



Vaccines and Global Health: The Week in Review
10 December 2022 :: Issue 683
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director

Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Coronavirus \[COVID-19\] - WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

Milestones, Perspectives

.....
.....

Gavi Board Decisions Outline “Year of Renewal” for Vaccine Alliance

- Board underlines commitment to end backsliding in routine immunisation, catching up coverage and reaching zero-dose children as the Vaccine Alliance’s core priorities for the remainder of the current 2020–2025 strategic period
- The Board also affirmed Gavi’s critical role in fighting outbreaks and pandemic preparedness and response, and approved its current COVID-19 vaccination strategy – alongside support for exploring future integration with Gavi core programming
- New initiatives approved include a relaunch of HPV vaccination, an innovative plan to support vaccine manufacturing in Africa and other regions, and support to countries and communities confronting multiple global challenges

Geneva, 8 December 2022 – The Board of Gavi, the Vaccine Alliance today **approved an evolution of its current 5-year programme strategy that will see renewed focus on routine immunisation and reaching zero-dose children, new vaccine introductions, a strengthened Alliance role in outbreak and pandemic preparedness and response, alongside continued COVID-19 vaccinations in the 92 lower income** countries supported by the Gavi COVAX Advance Market Commitment. Professor José Manuel Barroso, Chair of the Board, was confirmed for a second, three-year term.

The two-day meeting, which concluded today, also **approved a relaunch of the Alliance’s HPV vaccination programme. An ambitious plan to support sustainable regional vaccine manufacturing, particularly in Africa,** was also adopted.

The Board also gave a green light to leverage Gavi’s decades-long experience combatting the continuum of outbreaks, epidemics and pandemics, including with the recent learnings from COVAX, for pandemic preparedness and response (PPR) – in particular working towards equitable access to outbreak and pandemic vaccines, strengthening health systems, accelerating at-risk innovative financing and supporting diversification of global vaccine manufacturing.

A decision to continue ensuring COVID-19 vaccines are accessible to the 92 AMC countries was also approved by the Board. While the current priority remains to help countries raise coverage levels and boost high risk groups, the Board also endorsed plans to start preparing now for future evolutions of the virus. While COVAX continues to have in place plans for worst case scenarios, **the Board agreed, in principle, to explore integrating future COVID-19 vaccinations into Gavi’s core programming** – in a bid to improve synergies, be more responsive to countries’ needs and reduce the additional burden a specialized emergency response places on countries. This approval in principle will help Gavi engage with countries and partners on what shape a future programme would take, while also remaining flexible in case of further developments in 2023.

“Never before have Gavi-supported countries administered as many vaccines as the billions of doses they did in 2021. Yet routine immunisation has been impacted hard by the pandemic for two consecutive years and it is essential that we help countries to address this. The decisions taken at this week’s meeting will help the Vaccine Alliance enter a Year of Renewal; not only its historical mission to

leave no one behind with immunisation but of the Alliance itself, introducing new innovations and ways of working learned from the pandemic,” said Professor José Manuel Barroso, Chair of the Board of Gavi.

Further details on the decisions made at the Board Meeting include:

- **Gavi’s Board expressed overwhelming support for the relaunch of the HPV vaccine programme with over US\$ 600 million investment.** The money will go towards funding vaccines, strengthening health systems and providing technical and learning support. With cervical cancer causing 342,000 deaths in 2020, 90% of which occurred in low- and middle-income countries, the HPV vaccine is one of the most impactful vaccines in Gavi’s portfolio. With the new funding in place, the Alliance has set an ambitious goal to reach over 86 million girls by 2025, aiming to avert over 1.4 million future deaths from cervical cancer.
- A plan to support the **development of a regionally diversified vaccine manufacturing ecosystem** was also approved. Based on three pillars; support for strategic antigen selection by manufacturers/countries, market shaping and demand creation, the initiative represents a major step forward in addressing one of the critical challenges faced during the pandemic: how to ensure all regions of the world have the ability to manufacture vaccines. The initiative, supported by the African Union, Africa CDC, G7 and other stakeholders, also envisages the possibility of a fourth pillar, the design of a new financial instrument in the form of an Advance Market Commitment (AMC) for African vaccine manufacturing. This will be developed over the coming year, for potential approval and launch in 2023.
- Recognising that countries and communities face increased fragility and multiple challenges, the Board sought to balance ensuring access with sustainability through Gavi transition and co-financing policies. **The Board extended timeframes for countries scheduled to transition out of Gavi support, put in place lower, time-limited, co-financing requirements for new malaria vaccines, extended the Gavi eligibility and co-financing exemptions for inactivated polio vaccine (IPV) in support of polio eradication efforts, and confirmed zero co-financing requirements for outbreak response and refugee populations currently not integrated into national plans.**

“Gavi’s mission, working together as Alliance to deliver unparalleled impact, has always been to help countries protect their populations through immunisation. As we move out of the emergency phase of the pandemic, this will mean catching up on essential and sustaining COVID-19 vaccinations, helping them plan and prepare for the increasing occurrence of outbreaks due to climate change and growing populations – and looking further ahead, putting in place a global health response that will enable us to address future pandemics and global health security threats much more effectively,” said Dr Seth Berkley, CEO of Gavi.

Appointments and Process Updates

In addition, a number of appointments were made or reconfirmed:

- Prof José Manuel Barroso was reappointed for a new term as Board Chair.
- Mphu Ramatlapeng, Gabriella Fésüs, Saad Omer and Andrew (Drew) Otoo were appointed to join the board on 1 January 2023. They replace Margaret (Peggy) Hamburg, Bernhard Braune, Marta Nunes and Roger Connor respectively. John Arne Røttingen was reappointed to the board.
- Jérémie Forrat-Jaime, Rhoda Wanyenze and Joan Benson were appointed, and Francesca Manno and Joris Jurriëns were reappointed, as alternate members. Yibing Wu was appointed as Chair of the Investment Committee.



The Rockefeller Foundation and Digital Square at PATH Commit \$5M to Strengthening Data-Driven Health Systems & Global Immunizations

Dec 07 2022 *Press Releases*

Two-year partnership will support deployment of digital tools and data analytics in Jamaica, Mali, Tanzania, Thailand, Uganda, and Zambia

NEW YORK | December 7, 2022 – **The Rockefeller Foundation and PATH announced the Digital Results Improve Vaccine Equity and Demand (DRIVE Demand) project, a two-year, US\$5 million partnership** with PATH's Digital Square initiative to deploy and expand the use of digital health tools in **Jamaica, Mali, Tanzania, Thailand, Uganda, and Zambia**. Through DRIVE Demand, the partners aim to help ministries of health utilize digital technologies to understand, track, and influence demand for immunizations. Ultimately, it will support target countries' effort to reach national Covid-19 and routine immunization targets, while strengthening data-driven health systems in Asia, the Caribbean, and Sub-Saharan Africa...

The six focus countries were chosen based on an evaluation of their responses to Covid-19, including: vaccine demand; vaccination rates (both low and high); use of existing open source global good digital health platforms or systems; and intersection with The Rockefeller Foundation's Vaccination Access Network (VAN). The results of this evaluation led to a country-by-country approach to activity generation, which was created with government leaders to ensure that the program aligned with government priorities and responded to individual country needs...

In addition to supporting Covid-19 vaccination efforts, the **DRIVE Demand project will also guide partners through the process of digitizing existing health record systems and integrating software while applying learnings from Covid-era innovations to routine immunizations and future pandemic preparedness...**

The funding for DRIVE Demand is part of The Rockefeller Foundation's Global Vaccination Initiative (GVI), a two-year, \$55 million effort launched in April 2022 to support country-led Covid-19 immunization campaigns in Africa, Asia, Latin America, and the Caribbean.

About Digital Square

Digital Square is a PATH-led initiative funded by the Rockefeller Foundation, the United States Agency for International Development (USAID), the Bill & Melinda Gates Foundation, and a consortium of other partners to advance digitally enabled health services around the world to help close the health equity gap. Since its inception in 2016, Digital Square has raised nearly \$115M to catalyze a range of digital health investments in support of the adoption, adaptation, and scaling of interoperable digital technologies to improve global health equity. Digital Square's coalitions, resources, and community of mature digital public goods for health (global goods) support large-scale, high-quality, sustainable implementations of digital health interventions.



Global spending on health: rising to the pandemic's challenges

WHO

8 December 2022

Overview

The results of the report clearly show that in 2020, a year dominated by the emergence of COVID-19 and its associated health and economic crises, governments around the world rose to the challenge.

Sharp increases in government spending on health at all country income levels underpinned the rise in health spending to a new high of US \$9 trillion (approximately 11% of global GDP). Government health spending generally increased and offset declines in out-of-pocket spending. Importantly, the rise in government health spending was part of a much broader fiscal response to the pandemic. In high income and upper-middle income countries social protection spending also increased sharply in as governments attempted to cushion populations from the economic impacts of COVID-19. In contrast to health and social protection, growth in education spending was relatively subdued. Countries face the further challenge of sustaining increased public spending on health and other social sectors in the face of deteriorating macroeconomic conditions and rising debt servicing. This also includes the challenge of sustaining external support for low income countries, which is essential for reducing ensuring poverty, ensuring access to health services and strengthening pandemic preparedness.

Higher health spending in response to a global pandemic

- In 2020, global spending on health reached US\$ 9 trillion, or 10.8% of global gross domestic product (GDP), and was highly unequal across income groups.
- Across countries, health spending in 2020 rose in per capita terms and as a share of GDP across all income groups.
- Government spending was the main driver of the increase in total health spending from 2019 to 2020. Per capita government spending on health increased in all income groups and rose faster than in previous years.
- Health spending as a share of total government expenditure, an indicator of the priority given to health, increased from 2019 to 2020 in all income groups except high income countries.
- Out-of-pocket spending per capita fell during the first year of the pandemic, which may reflect reduced health service utilization.
- External aid continued to play a critical role in low income countries. From 2019 to 2020, per capita health spending from aid increased marginally in low income countries.

.....
.....

World malaria report 2022

Global Report - 8 December 2022 :: 372 pages

PDF: <https://apps.who.int/iris/rest/bitstreams/1484818/retrieve>

Overview

Each year, WHO's World malaria report offers in-depth information on the latest trends in malaria control and elimination at global, regional and country levels. The report highlights progress towards global targets and describes opportunities and challenges for curbing and eliminating the disease.

This year's report includes 3 new sections on: (1) global and regional initiatives launched in 2021 and 2022; (2) global malaria surveillance and country-level case studies on surveillance systems assessments; and (3) research and development. The report also includes an expanded section on threats to malaria control, with a focus on the declining effectiveness of insecticide-treated mosquito nets.

Despite continued impact of COVID-19, malaria cases and deaths remained stable in 2021

News release Geneva, Switzerland

8 December 2022

New data released today by the World Health Organization (WHO) show that countries around the world largely held the line against further setbacks to malaria prevention, testing and treatment services in 2021.

According to this year's World malaria report, there were an estimated 619 000 malaria deaths globally in 2021 compared to 625 000 in the first year of the pandemic. In 2019, before the pandemic struck, the number of deaths stood at 568 000.

Malaria cases continued to rise between 2020 and 2021, but at a slower rate than in the period 2019 to 2020. The global tally of malaria cases reached 247 million in 2021, compared to 245 million in 2020 and 232 million in 2019.

"Following a marked increase in malaria cases and deaths in the first year of the COVID-19 pandemic, malaria-affected countries redoubled their efforts and were able to mitigate the worst impacts of Covid-related disruptions to malaria services," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "We face many challenges, but there are many reasons for hope. By strengthening the response, understanding and mitigating the risks, building resilience and accelerating research, there is every reason to dream of a malaria-free future."...

.....
.....

Pharmaceutical industry statement delivered at CBD COP 15 meeting regarding Digital Sequence Information and the need for special measures for pathogen sharing

Published on: 07 December 2022

IFPMA is grateful for the opportunity to participate in the COP15 negotiations. The importance of biodiversity conservation and sustainable use has become more and more pressing, and IFPMA, the body representing the innovative pharmaceutical industry in official relations with the ECOSOC/United Nations, hopes that a successful negotiation of the Post-2020 Global Biodiversity Framework will allow countries to come together to address biodiversity loss across the globe.

The COVID-19 pandemic has, however, highlighted flaws in the implementation of the Nagoya Protocol that greatly restrict the speed, certainty, and ease at which pathogens can be shared. The negative impact of the implementation of the Nagoya Protocol on public health has been significant and could have even more serious effects. We've seen these negative consequences in the sharing of seasonal and pandemic influenza, SARS-CoV-2, Zika, Monkeypox, Japanese Encephalitis, Foot and Mouth Disease, African Swine Fever, and bacterial isolates important for assessing antimicrobial resistance. The way many countries have decided to implement the Nagoya Protocol domestically has led to delays of up to 18 months in the sharing of pathogens, or stopped it altogether.

Pathogens cannot be treated in the same way as other genetic resources – delays in accessing pathogens in pre-pandemic and pandemic situations can have devastating effects on human lives as well as society at large. Ensuring immediate and unhindered

pathogen sharing, through a public health exemption to access and benefit (ABS) rules, is critical for the future of public health.

According to our analysis, an overwhelming majority of Parties to the Nagoya Protocol have not implemented their obligation under Article 8(b) of the Protocol, with only 12 jurisdictions out of 137 having implemented some form of public health exemption. More often than not, this exemption does not provide clarity or speed up the sharing of pathogens. This has weakened legal certainty for R&D despite the willingness and efforts of pharmaceutical companies, research laboratories and the WHO to work with national governments.

Regarding negotiations on digital sequence information (DSI), any policy option or mechanism currently under consideration by member states must include an exemption for pathogens in order to prevent delays in the sharing of pathogens. The current options, as they are formulated, could have serious consequences for the surveillance of pathogens, as they are not specially tailored for the world of public health and thus risk undermining ongoing and future pandemic preparedness and response efforts.

The above points demonstrate that (i) the current ABS system for genetic resources is not working and (ii) that pathogens require special expedited measures. These two issues must be resolved before any new DSI system is implemented. IFPMA is of the firm belief that no ABS system, as proposed, should apply to DSI and that pathogens must be excluded from the scope of the CBD.

.....
.....

WHO Member States agree to develop zero draft of legally binding pandemic accord in early 2023

7 December 2022 *News release Geneva*

- Countries meet for three days to agree next steps toward historic legal instrument, rooted in the WHO Constitution, designed to protect world from future pandemics.
- During discussions, Member States call for global agreement that takes into account equity, promotes preparedness, ensures solidarity and respects sovereignty.
- Zero draft of the pandemic accord to be ready for negotiations by Member States starting February 2023.

Member States of the World Health Organization today agreed to develop the first draft of a legally binding agreement designed to protect the world from future pandemics. This “zero draft” of the pandemic accord, rooted in the WHO Constitution, will be discussed by Member States in February 2023.

Today’s agreement by the Intergovernmental Negotiating Body (INB), comprised of WHO’s 194 Member States, was a milestone in the global process to learn from the COVID-19 pandemic and prevent a repeat of the devastating impacts it has had on individuals and communities worldwide. The INB gathered at WHO headquarters in Geneva from 5-7 December for its third meeting since its establishment in December 2021, following a special session of the World Health Assembly.

The Body today agreed that the INB’s Bureau will develop the zero draft of the pandemic accord in order to start negotiations at the fourth INB meeting, scheduled to start on 27

February 2023. This draft will be based on the conceptual zero draft and the discussions during this week's INB meeting. The INB Bureau is comprised of six delegates, one from each of the six WHO regions, including the Co-Chairs Mr Roland Driec of the Netherlands and Ms Precious Matsoso of South Africa...

.....
.....

China – COVID Response

Editor's Note:

We have noted over many months that official China public health channels have severely limited reporting on COVID response and policy. The recent and still emerging shift from the zero-COVID strategies of the last few years, apparently triggered by mass protests across the country and other pressures, has triggered significant global media coverage and analysis.

The clash of political power and evidence-based public health policy has occurred at too many points in global pandemic response and in different national contexts, including the U.S. Given the apparent milestone reached in the PRC context, we include a small selection of media reports below [clearly not exhaustive, clearly Global North-weighted, but hopefully indicative].



DEC 3RD 2022

China's covid failure

Leaders / China and the pandemic

Xi Jinping's zero-covid policy has turned a health crisis into a political one

Caught between raging disease and unpopular and costly lockdowns, he has no good fix

CHINA INVENTED covid-19 lockdowns. During the first weeks of the pandemic, the government of Xi Jinping corralled tens of millions of people to stop the disease spreading out of Wuhan. Almost three years later, lockdowns have become China's undoing. A combination of protests and rising cases means that Mr Xi will have to navigate between mass lockdowns and mass infection—and possibly end up with both. The coming months will pose the biggest threat to his rule since he came to power in 2012 and the biggest threat to the authority of the Communist Party since the protests around Tiananmen Square in 1989...

.....

Financial Times

10 Dec 2022

Opinion - Chinese politics & policy

China faces an uncertain future in the zero-Covid endgame

Despite official triumphalism, rolling back the policy could see the health system overwhelmed

James Kynge

The Chinese took the art of cryptic demonstrations to new heights last week. Well aware of the perils of protest in an authoritarian state with about 600mn surveillance cameras, the crowds of people who turned out to criticise Beijing's stifling "zero-Covid" regime did so in a number of ingenious ways.

One group of students from the elite Tsinghua University in Beijing held aloft sheets of paper bearing a mathematical equation that describes the expansion of the universe. The message, it turned out, was that the equation had been developed by Alexander Friedmann, whose name sounds like "Free Man" — and freedom is what the protesters were calling for...

The protests, which took place in more than 20 cities, have ended. But the demands of the demonstrators to unwind zero-Covid are being met, at least in part. After nearly three years of subjecting 1.4bn people to a regime of mass testing, travel curbs and rolling urban lockdowns, Beijing is lifting or relaxing restrictions in cities across the country.

These are certainly momentous times. But it is unlikely that the sudden policy shift represents meek acquiescence towards the street protests by Xi Jinping, China's strongman leader. A much more plausible explanation is that the change of heart was prompted by a build-up of discontent within the vast Communist party hierarchy as the economy stuttered, youth unemployment surged and education was disrupted...

The big risks, however, concern what comes next. China is in uncharted territory: a dash towards herd immunity could cause the deaths of as many as 1mn people in a massive "winter wave" of infections, according to recent mathematical modelling by Wigram Capital Advisors, an Asia-focused macroeconomic advisory group.

Under a scenario in which China's leadership continues to roll back zero-Covid, the national health system would quickly become overwhelmed. With daily fatalities reaching as high as 20,000 in mid-March, demand for intensive care units would peak at 10 times higher than capacity by late March, according to the Wigram Capital Advisors' model. Aside from the human cost, the political fall out could

be intense. Xi has been hailed by the state media as the “commander-in-chief of the people’s war against Covid”. He has boasted that China’s response to the pandemic — which has kept officially reported total deaths down to the very low number of 5,235 — demonstrated the “superiority” of the country’s system.

If deaths start to rise sharply, it will not only mark a personal failure for Xi. It will also raise questions about his judgment and the ability of China’s highly centralised power structure to make wise decisions...

.....

Financial Times

09 Dec 2022

[China’s disappearing data stokes fears of hidden Covid wave](#)

Low official case number and death toll puzzle analysts after Beijing lifts Covid testing requirements

Edward White in Seoul and Qianer Liu in Hong Kong

China is under-reporting coronavirus cases and fatalities, obscuring the scale and severity of the health crisis just as the world’s most populous country enters its deadliest phase of the pandemic, analysts warn.

Official statistics on Friday revealed no new deaths and only 16,363 locally transmitted coronavirus cases in China, less than half the peak caseload reported last month.

That is despite a stunning U-turn over the past week to relax President Xi Jinping’s heavy-handed pandemic controls, which means the virus is certain to spread.

The sweeping changes to Xi’s zero-Covid policy allow asymptomatic or mild cases to isolate at home rather than in centralised quarantine, and slashed China’s mass testing and contact tracing requirements.


The sudden reversal came weeks after Covid-19 cases hit a record high of more than 40,000 a day, with every region of the country reporting an Omicron outbreak.

Despite the official numbers suggesting the caseload had halved, Raymond Yeung, China economist at ANZ bank, said that on-the-ground observations indicated some cities, including Baoding, in the northern province of Hebei, already had “high infection numbers”. More big cities, he said, would soon endure similar levels of infections.

“Like Hong Kong, the actual infection data will no longer be informative. As the ‘official’ infection figures decline, the government can eventually claim their success against the virus,” Yeung said.

The situation echoes the dearth of official information during the disastrous initial outbreak in Wuhan nearly three years ago. Local officials and analysts warned that the reduced testing, as well as gaps in reporting of both cases and deaths, would make it harder to assess the risk to the world’s second-biggest economy.

"The behaviour of case numbers is very similar to 2020, where we had one [to] two weeks with genuine case numbers, before the veil was drawn," said Rodney Jones, principal at Wigram Capital Advisors, an Asia-focused macroeconomic advisory group.



"We have no idea whether we will see actual case data again, and whether the sharp downshift in cases reflects reduced testing . . . or political management of the case data," Jones added.

A critical missing piece of information is the rate of positive tests, which is important for determining actual infection. Nor is the real-time effective R value published, depriving observers of a vital measure of the rate at which the disease is spreading.

There are also discrepancies between Chinese regions in how cause of death is determined and the definition of "symptomatic". In some cities, including Shanghai, a chest scan is required before Covid diagnosis.

Xi's decision to loosen strictures has led to fears of an unparalleled wave of infections and a sharply rising death toll. Wigram has projected as many as 1mn deaths over the winter months...

.....

New York Times

December 9, 2022 08:14 am ET

China

China's Covid-19 Reversal Sparks Rush for Medicines, Vaccines

After years saying the virus is too deadly to live with, leaders now risk a lethal surge in infections.
Selina Cheng

December 8, 2022 08:33 am ET

China

China Braces for Deadly Covid Wave After Loosening Controls

Strained hospitals and the country's poor vaccination rates could lead to over a million deaths, according to some public health experts. "It will put unprecedented strain on the Chinese health system," a scientist said.

Sha Hua and Liyan Qi

Appeared in the Dec 09, 2022 , print edition as 'Beijing Is Bracing for a Deadly Covid-19 Wave'

.....
.....
.....

PHEIC

Coronavirus [COVID-19] - WHO

Public Health Emergency of International Concern (PHEIC)

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

Weekly Epidemiological and Operational updates

Last update: 9 Dec 2022

Confirmed cases :: 643 875 406

Confirmed deaths :: 6 630 082

Vaccine doses administered: 12 998 974 878


.....

Weekly epidemiological update on COVID-19 – 7 December 2022

Overview

Globally, the number of new weekly cases remained stable (-3%) during the week of 28 November to 4 December 2022 as compared to the previous week with just under 3 million new cases reported. The number of new weekly deaths decreased by 17% as compared to the previous week with about 7800 fatalities reported. As of 4 December 2022, over 641 million confirmed cases and 6.6 million deaths have been reported globally....

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 4 December 2022**



■■■■■
■■■■■

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 10 Dec 2022

An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 3/20/2022 reported]



50

vaccines **approved for use** by at least one national regulatory authority ¹



11

vaccines in WHO's **Emergency Use Listing**



1.87bn

doses **shipped through COVAX** to **146** countries



\$2 - \$120

reported vaccine **price range** per dose



18.0bn

doses **secured globally**



46K

novel oral antiviral **therapeutic treatments** arrived in **9** countries


■■■■■
■■■■■

Global Dashboard on COVID-19 Vaccine Equity

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 10 Dec 2022]: <https://data.undp.org/vaccine-equity/>

See also visualization on [Vaccine Access](#) and [Vaccine Affordability](#)



.....

COVID-19 Global Targets and Progress Tracker - IMF

The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.

The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.

.....

COVID Vaccines – OCHA:: HDX

COVID-19 Data Explorer: Global Humanitarian Operations

COVID-19 Vaccine Roll-out

DEC 10 2022 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

Global COVID-19 Figures: 121M total confirmed cases; 2.3M total confirmed deaths

Global vaccines administered: 13.0B

Number of Countries: 28

COVAX Allocations Round 4-9 (Number of Doses): 170M

COVAX Delivered (Number of Doses): 390M

Other Delivered (Number of Doses): 420M

Total Delivered (Number of Doses): 800M

Total Administered (Number of Doses): 540M

.....


Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]

<https://data.covid19taskforce.com/data>

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed **10 Dec 2022**: <https://data.covid19taskforce.com/data> The global view below is complemented by country-specific dashboards [here](#).



.....
.....

Our World in Data

Coronavirus (COVID-19) Vaccinations [Accessed 10 Dec 2022]

:: [68.6%](#) of the world population has received at least one dose of a COVID-19 vaccine.

:: [13.04 billion doses](#) have been administered globally, and [2.35 million](#) are now administered each day.

:: [24.9%](#) of people in low-income countries have received at least one dose.

.....
.....

Duke – Launch and Scale Speedometer

The Race for Global COVID-19 Vaccine Equity

See our COVID Vaccine Purchases research

See our COVID Vaccine Manufacturing research



See our COVID Vaccine Donations & Exports research

Overview of donations by top 10 donating countries

Bar chart is ordered by total number of doses pledged.
Donut charts are ordered by proportion of pledged donations shipped.

Country Category:
Top 10 Donating Countries

Pledged doses
Total Shipped




Remaining	Total Shipped
662,599,048	1,550,169,430

Data updated on December 9th 2022

.....
.....

Global COVID-19 Access Tracker
<https://www.covid19globaltracker.org/>



.....
.....

U.S.: COVID-19/Vaccines – Announcements/Regulatory Actions/Deployment

HHS

News

[Letter to U.S. Governors from HHS Secretary Xavier Becerra on COVID-19, Flu, and RSV Resources](#)

December 9, 2022 | News Release

[Statement from HHS Secretary Xavier Becerra on CDC's Recommendation of the Updated COVID-19 Vaccines for Young Children](#)

December 9, 2022 | News Release

[Statement From HHS Secretary Becerra on mpox](#)

December 2, 2022 | News Release

FDA

Press Announcements

[Coronavirus \(COVID-19\) Update: FDA Authorizes Updated \(Bivalent\) COVID-19 Vaccines for Children Down to 6 Months of Age](#)

December 8, 2022

.....
.....

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency

News & Press Releases

[News: ETF warns that monoclonal antibodies may not be effective against emerging strains of SARS-CoV-2 \(new\)](#)

Last updated: 09/12/2022

[News: ECDC and EMA collaborate on vaccine safety and effectiveness monitoring studies \(new\)](#)

Last updated: 08/12/2022

[News: ETF concludes that bivalent original/Omicron BA.4-5 mRNA vaccines may be used for primary vaccination \(new\)](#)

Last updated: 06/12/2022

.....

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News [Selected]

News

[Ebola outbreak in Uganda, as of 06 December 2022](#)

Epidemiological update - 9 Dec 2022

News

[Weekly COVID-19 country overview](#)

Epidemiological update - 9 Dec 2022

News

[Joint ECDC-WHO Europe COVID-19 surveillance bulletin](#)

Epidemiological update - 9 Dec 2022

News

[ECDC and EMA collaborate on vaccine safety and effectiveness monitoring studies](#)

Press release - 8 Dec 2022

.....

.....

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment

<https://africacdc.org/covid-19-vaccination/>



Africa CDC COVID-19 Vaccine Dashboard

Safeguarding Africa's Health

Vaccine Overview

Vaccination Coverage

Vaccine Supply

Vaccine Utilization

Vaccine Policy

Vaccine Delivery Targets

Member State Vaccine Summary



.....
.....

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

No new digest content identified. Last press release issued 31.08.2022.

.....
.....

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare

<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :
11 December 2022, 08:00
IST (GMT+5:30)

(↑↓ Status change since
yesterday)

Active (0.01%)

3913

Discharged (98.80%)

44140251

Deaths (1.19%)

530658

COVID-19 Vaccination
as on : 11 December
2022, 08:00 IST
(GMT+5:30)

Total Vaccination : 2,19,97,09,049 (40,744 ↑)

Government of India – Press Information Bureau

Latest Press Releases

No new digest content identified.

Indian Council for Medical Research (ICMR)

<https://www.icmr.gov.in/media.html>

Press Releases

No new digest content identified.

.....
.....

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[We did not identify any substantive, official announcements about China's COVID response in general, or in Shanghai, Beijing or other China locations.]

China's Xi unwilling to accept vaccines despite protests, U.S. official says

Reuters

1 hour ago

Beijing, Shenzhen loosen more COVID curbs as China fine-tunes policy

Reuters

9 hours ago

.....
.....
.....

PHEIC

Mpox

Public Health Emergency of International Concern (PHEIC)

<https://www.who.int/emergencies/situations/monkeypox-oubreak-2022>

1 December 2022

Multi-country outbreak of mpox, External situation report #11 - 1 December 2022

Highlights

:: Following a series of consultations with global experts, WHO will begin using the term "mpox" as the preferred name for the disease of monkeypox. Both names will be used simultaneously for one year while "monkeypox" is phased out. During the week of 21 to 27 November 2022, the number of mpox cases reported globally continued to decline.

:: In the week commencing 21 November, the Eastern Mediterranean Region has reported six new cases after five consecutive weeks without cases. These are retrospective reports of cases diagnosed between 1 October and 25 November 2022.

:: Since the last situation report published on 16 November, 1696 new cases (2.1% increase in total cases) and five new deaths have been reported.

:: Since the beginning of the outbreak, a high prevalence of HIV infection (52%; 14 573/28 006) has been reported among cases with known HIV status.

:: The proportion of cases among females has been gradually increasing since the beginning of the outbreak, reaching 6.7% as of 20 November 2022

.....
.....
.....

PHEIC

Polio

Polio this week as of 07 December 2022 - GPEI

:: In Africa, to reinvigorate political attention and action on immunization across the continent, H.E. Macky Sall, Chair of the African Union and President of the Republic of Senegal, will bring together Heads of State, civil society organizations, and other key stakeholders at the Forum on Immunization and Polio Eradication on 10 December in Dakar, Senegal, to remobilize leadership around the Addis Declaration on Immunization.

:: PBS feature on polio and immunization in DR Congo: the piece focuses on efforts to provide routine immunization to children, including during the pandemic, highlighting how local healthcare workers are responding to various challenges.

:: In Pakistan, a high-level delegation led by Polio Oversight Board (POB) Chair Dr Chris Elias, WHO Regional Director for the Eastern Mediterranean Dr Ahmed Al-Mandhari and UNICEF Regional Director George Laryea-Adjei, concluded there is unprecedented support and commitment to ending polio in the country in 2023. More.

Summary of new polioviruses this week:

- Pakistan: two WPV1 positive environmental samples
- Benin: three cVDPV2 cases and two positive environmental samples
- CAR: one cVDPV2 positive environmental sample
- Ghana: one cVDPV2 case and one positive environmental sample
- Madagascar: three cVDPV1 cases and 13 positive environmental samples
- Mozambique: two cVDPV1 cases
- Niger: two cVDPV2 cases and four positive environmental samples
- Togo: one cVDPV2 case

.....
.....

UN OCHA – Current Emergencies

Current Corporate Emergencies

Afghanistan

No new digest content identified.

Northern Ethiopia

Ethiopia - Situation Report, 6 Dec 2022

Somalia

No new digest content identified.

Ukraine

Highlights Last Updated: 29 Nov 2022

.....
.....

WHO & Regional Offices [to 10 Dec 2022]

<https://www.who.int/news>

Selected News/Announcements/Statements

9 December 2022

News release

[Report signals increasing resistance to antibiotics in bacterial infections in humans and need for better data](#)

9 December 2022

News release

[Ebola trial candidate vaccines arrive in Uganda in record 79 days after outbreak declared](#)

9 December 2022

Departmental news

[Moving WHO guidance on antibiotics into the heart of clinical practice](#)

8 December 2022

News release

[Despite continued impact of COVID-19, malaria cases and deaths remained stable in 2021](#)

8 December 2022

Departmental news

[The European Union and WHO further enhance their partnership for stronger pandemic preparedness and response](#)

7 December 2022

News release

[WHO Member States agree to develop zero draft of legally binding pandemic accord in early 2023](#)

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region

:: [COVID-19 burden lessens in Africa, vigilance crucial as year-end season begins](#)

08 December 2022 Brazzaville – While Africa is witnessing its lowest level of new COVID-19 cases since the onset of the pandemic, a recent four-week rise—the first such sustained increase in four months—underscores the criticality of maintaining vigilance as the end-year holiday seasons sets in...

:: [Bolstering Africa's health emergency readiness and response](#)

06 December 2022 Brazzaville – The World Health Organization (WHO) Regional Office for Africa in partnership with Africa Centres for Disease Control and Prevention, West African Health Organization, United States Centers for Disease Control and Prevention, UK Health Security Agency, Robert Koch Institute and the Bill and Melinda Gates Foundation today kicked off the region's largest public health emergency operation centre (PHEOC) simulation exercise to step up readiness to respond to public health emergencies, with 36 countries taking part in the two-day functional exercise.

WHO Region of the Americas PAHO

:: [Report signals increasing resistance to antibiotics in bacterial infections in humans and need for better data](#)

9 December 2022, GENEVA – A new World Health Organization (WHO) report reveals high levels of resistance in bacteria, causing life-threatening bloodstream infections, as well as increasing resistance

to treatment in several bacteria causing common infections in the community based on data reported by 87 countries in 2020. For the first time, the...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

:: 9 December 2022 News release

[**New WHO Signature Initiative paves the way for better heart health**](#)

:: 9 December 2022 News release

[**Ukraine endorses roadmap on mental health during the war**](#)

:: 8 December 2022 News release

[**Health for all: Meeting the needs of children and adolescents through enabling policies**](#)

WHO Western Pacific Region

:: [**Stories of hardship and hope: Towards zero leprosy in Cambodia**](#)

5 December 2022

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

8 December 2022 | [**Ebola disease caused by Sudan ebolavirus – Uganda**](#)

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected Titles

9 December 2022

[**The WHO AWaRe \(Access, Watch, Reserve\) antibiotic book**](#)

9 December 2022

[**Global antimicrobial resistance and use surveillance system \(GLASS\) report: 2022**](#)

9 December 2022

[**The WHO AWaRe \(Access, Watch, Reserve\) antibiotic book - Infographics**](#)

8 December 2022

[**Global spending on health: rising to the pandemic's challenges**](#)

8 December 2022

[**World malaria report 2022**](#)

8 December 2022

[**An investment case for new tuberculosis vaccines**](#)

Overview

This document summarizes the results of the WHO-commissioned full value proposition for new tuberculosis (TB) vaccines. The assessment was commissioned to provide early evidence for national and global decision-makers involved in TB vaccine development and implementation, who include stakeholders involved in vaccine research, financing, regulation and policy-making, manufacturing, introduction and procurement. The goal is to accelerate development of effective vaccines against TB and their rapid introduction into countries.

8 December 2022

[Improving the usability and impact of WHO guidelines: report of a WHO workshop](#)

8 December 2022

[UNICEF and WHO joint programme on mental health and psychosocial well-being and development of children...](#)

.....

.....

.....

CDC/ACIP [U.S.] [to 10 Dec 2022]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

Latest News Releases

[CDC Studies Support Mpox Vaccine as Safe and Effective](#)

December 9, 2022 Studies show vaccinated people have substantially less risk for contracting mpox compared with those who are unvaccinated and identified no major safety concerns after nearly 1 million doses administered.

[CDC Expands Updated COVID-19 Vaccines to Include Children Ages 6 Months through 5 Years](#)

December 9, 2022 Following FDA action, today CDC expanded the use of updated (bivalent) COVID-19 vaccines for children ages 6 months through 5 years.

[Transcript: CDC Media Telebriefing - Update on Respiratory Disease Circulation](#)

December 8, 2022

... As we are all aware, nationally, we are seeing elevated levels of respiratory viruses including RSV, flu and COVID-19. Especially for RSV and flu, these levels are higher than we generally see this time of year. Levels of flu like illness, which includes people going to the doctor with a fever and a cough or sore throat are at either high or very high levels in 47 jurisdictions and that is up from 36 jurisdictions just last week. CDC estimates that since October 1, there have already been at least 8.7 million illnesses, 78,000 hospitalizations and 4500 deaths from flu. Flu hospital admissions reported through HHS's hospital surveillance system, which were already high for this time of year have nearly doubled during the last reporting period. Compared to the week prior hospitalizations for flu continue to be the highest we have seen at this time of year in a decade, demonstrating the significantly earlier flu season we are experiencing...

.....

ACIP Meetings

Next ACIP Meeting

No 2022 meetings identified.

.....

MMWR Weekly: Current Volume (71)

December 9, 2022 / No. 49

[PDF of this issue](#)

- [Progress Toward Poliomyelitis Eradication — Afghanistan, January 2021–September 2022](#)
- [Human Rabies — Texas, 2021](#)
- [Safety Monitoring of JYNNEOS Vaccine During the 2022 Mpox Outbreak — United States, May 22–October 21, 2022](#)
- [Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons — 43 U.S. Jurisdictions, July 31–October 1, 2022](#)

.....

Coronavirus Disease 2019 (COVID-19)- CDC

Announcements/reports/data summaries.

.....

.....

Africa CDC [to 10 Dec 2022]

<http://www.africacdc.org/>

News

Africa CDC convenes public health officials and experts to prepare the continent to respond to future outbreaks

5 December 2022

Public health officials, experts, researchers, and scientists around Africa will gather at a major conference at the African Union Commission in Addis Ababa, Ethiopia, this week to take stock of how ready, in a post-COVID-19 world, African countries are to face up to the next disease threat.

'Beyond COVID-19: Pathogen Genomics and Bioinformatics for Health Security in Africa' will be hosted by the Africa Centres for Disease Control and Prevention (Africa CDC), the autonomous health institution of the African Union (AU). The meeting will be held at the AU's Headquarters in Addis Ababa from 29 November to 1 December 2022.

The event will draw around 120 public health officials, researchers, and scientists from 49 AU Member States, as well as local and international partners.

The symposium will, in particular, focus on the existing capacity along the full value chain of pathogen genomics and bioinformatics. This entails everything from the sequencing and analysing of disease-causing pathogens, to issues of supply chain, the generation and sharing of data, as well as international policies and agreements that govern how these processes should unfold.

Participants will review the progress, challenges and lessons from the rapid expansion of pathogen

genomics in Africa, through the Africa CDC's Africa Pathogen Genomics Initiative (Africa PGI) and the work of other stakeholders over the past two years...

.....
.....

China CDC

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 10 Dec 2022]

<http://en.nhc.gov.cn/>

News

Dec 10: Daily briefing on novel coronavirus cases in China

On Dec 9, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 3,082 new cases of confirmed infections.

National Medical Products Administration – PRC [to 10 Dec 2022]

<http://english.nmpa.gov.cn/>

Chinese mainland reports 4,351 new local confirmed COVID-19 cases

2022-12-07

The Chinese mainland on Tuesday reported 4,351 locally transmitted confirmed COVID-19 cases, the National Health Commission said Wednesday.

China CDC Weekly Reports: Current Volume (4)

2022-12-09 / No. 49 WORLD ANTIBIOTIC AWARENESS WEEK ISSUE

[View PDF of this issue](#)

- Preplanned Studies: Dissemination of Antibiotic Resistance Genes Among Patients with Diarrhea — Freetown, Sierra Leone, 2018
- Commentary: National Antibiotic Resistance Strategy for Human Health in France
- Perspectives: Current and Future Landscape of the Antimicrobial Resistance of Nosocomial Infections in China
- Perspectives: Minimizing Risks of Antimicrobial Resistance Development in the Environment from a Public One Health Perspective

.....
.....
.....

Organization Announcements

Paul G. Allen Frontiers Group [to 10 Dec 2022]

<https://alleninstitute.org/news-press/>

News

No new digest content identified.

BMGF - Gates Foundation [to 10 Dec 2022]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 10 Dec 2022]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications

No new digest content identified.

CARB-X [to 10 Dec 2022]

<https://carb-x.org/>

News

No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 10 Dec 2022]

<https://centerforvaccineethicsandpolicy.net/>

News/Analysis/Statements

:: Past weekly editions of [Vaccines and Global Health: The Week in Review](#) are [available here](#).

:: [Informed Consent: A Monthly Review – December 2022](#) is now posted [here](#)

CEPI – Coalition for Epidemic Preparedness Innovations [to 10 Dec 2022]

<http://cepi.net/>

Latest News

[CEPI boosts 'Coronavirus X' vaccine search with expanded VBI Vaccines deal](#)

Agreement expands CEPI's world-leading portfolio of variant-proof coronavirus vaccines that could be deployed against COVID-19 as well as a future 'Coronavirus X'

06 Dec 2022

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 10 Dec 2022]

<https://cioms.ch/>

News; Publications

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 10 Dec 2022]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 10 Dec 2022]

<https://dukeghic.org/>

Our Blog

No new digest content identified.

EDCTP [to 10 Dec 2022]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

08 December 2022

EDCTP and ICGEB sign Memorandum of Understanding

By signing the MoU, the EDCTP Association and ICGEB agree that they shall encourage and promote cooperation in the following areas of mutual interest in sub-Saharan Africa:

- 1) Bringing high-level genomic engineering technology into EDCTP-funded networks in sub-Saharan Africa for optimising the fight against poverty-related infectious diseases
- 2) Joint activities in capacity development related to development of interventions against these diseases...

Emory Vaccine Center [to 10 Dec 2022]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 10 Dec 2022]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified

Evidence Aid [to 10 Dec 2022]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

<http://www.evidenceaid.org/>

Resources [Selected]

Interventions for noncommunicable diseases in humanitarian emergencies in low- and middle-income countries

Added December 6, 2022

Fondation Merieux [to 10 Dec 2022]

<http://www.fondation-merieux.org/>
News, Events
No new digest content identified.

Gavi [to 10 Dec 2022]
<https://www.gavi.org/>
News Releases
8 December 2022
[Gavi Board Decisions Outline “Year of Renewal” for Vaccine Alliance](#)
[See Milestones above for detail]

GHIT Fund [to 10 Dec 2022]
<https://www.ghitfund.org/newsroom/press>
Press Releases December 5, 2022
[GHIT Fund Secures US\\$20 million pledge from Wellcome over 5 years](#)

Global Fund [to 10 Dec 2022]
<https://www.theglobalfund.org/en/news/>
News & Stories
No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 10 Dec 2022]
<https://www.glopid-r.org/news/>
News
No new digest content identified.

Hilleman Laboratories [to 10 Dec 2022]
<http://www.hilleman-labs.org/>
News & Insights
No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 10 Dec 2022]
<https://www.hhmi.org/news>
Press Room
No new digest content identified.

Human Vaccines Project [to 10 Dec 2022]
<http://www.humanvaccinesproject.org/>
News
IMMUNOME Report

Dec 08, 2022

Colin Carlson: Can Machine Learning Help Predict the Next Pandemic?

IAVI [to 10 Dec 2022]

<https://www.iavi.org/>

Latest News

FEATURES

December 7, 2022

Community-rooted science: a pathway to accelerating vaccine discovery

FEATURES

December 5, 2022

Meet the IAVI scientist on the cusp of developing a novel HIV vaccine candidate

ICRC [to 015 Oct 2022]

<https://www.icrc.org/en/whats-new>

What's New [Selected]

ICRC applauds UN Security Council's adoption of a resolution protecting humanitarian activities

New York (ICRC) - Today is an important day in the history of humanitarian action.

09-12-2022 | News release

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 10 Dec 2022]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press Releases [Selected]

IFRC welcomes landmark U.N. Security Council resolution as a critical step towards scaling up humanitarian action in crisis-hit countries

Geneva, 9 December 2021 – The International Federation of Red Cross and Red Crescent Societies (IFRC) welcomes the U.N. Security Council's landmark resolution protecting humanitarian action in countries where U.N. sanctions apply.

This resolution will facilitate the timely delivery of life-saving and timely support to people living in the most fragile and vulnerable environments...

Institut Pasteur [to 10 Dec 2022]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

ISC / International Science Council [to 10 Dec 2022]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Current

Press releases

[The International Science Council and Future Africa sign new agreement to co-design the ISC's presence in Africa](#)

08.12.2022

News

[ISC appoints new Fellows to support its mission to bring science to society](#)

05.12.2022

...The second cohort of Fellows includes eminent social and natural scientists, engineers and thought-leaders who have made impactful contributions in the science-policy sphere. They hail from different countries and regions, disciplines, sectors and career stages; having been nominated by ISC Members, Governing Board and Fellowship Council members, and sister networks like the Global Young Academy and InterAcademy Partnership. The three outgoing ISC patrons – Mary Robinson, Ismail Serageldin and Vint Cerf – have been awarded Honorary Fellowship status, in special recognition of their outstanding support to ISC...

News

[Statement by international science advisors in advance of COP 15](#)

05.12.2022

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

No new digest content identified.

IVAC [to 10 Dec 2022]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 10 Dec 2022]

<http://www.ivi.int/>

IVI News & Announcements
No new digest content identified.

Johns Hopkins Center for Health Security [to 10 Dec 2022]
<https://www.centerforhealthsecurity.org/news/center-news/>
Center News [Selected]
[Center Faculty Contribute to Commentary Published in *Science* About Strengthening Oversight of Research Involving Enhanced Potential Pandemic Pathogens](#)
December 8, 2022

MSF/Médecins Sans Frontières [to 10 Dec 2022]
<http://www.msf.org/>
Latest [Selected Announcements]
Afghanistan
[People with tuberculosis face multiple barriers accessing treatment in Afghanistan](#)
Project Update 8 Dec 2022

National Academy of Medicine - USA [to 10 Dec 2022]
<https://nam.edu/programs/>
News [Selected]
No new digest content identified.

National Academy of Sciences - USA [to 10 Dec 2022]
<http://www.nasonline.org/news-and-multimedia/>
News
No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 10 Dec 2022]
<https://www.hhs.gov/vaccines/about/index.html>
Upcoming Meetings/Latest Updates
No new digest content identified.

NIH [to 10 Dec 2022]
<http://www.nih.gov/>
News Releases
No new digest content identified.

PATH [to 10 Dec 2022]
<https://www.path.org/media-center/>
Press Releases
No new digest content identified.

Rockefeller Foundation [to 10 Dec 2022]

<https://www.rockefellerfoundation.org/>

Selected Reports/Press Releases

Dec 07 2022 *Press Releases*

Building Stronger Pandemic Preparedness With Infectious Disease Modelling

NONTHABURI, THAILAND | November 25, 2022 – The Health Intervention and Technology Assessment Program (HITAP) announced the completion of the first Technical Workshop on Infectious Disease Modelling. Research staff from ...

Dec 07 2022 *Press Releases*

The Rockefeller Foundation and Digital Square at PATH Commit \$5M to Strengthening Data-Driven Health Systems & Global Immunizations

Two-year partnership will support deployment of digital tools and data analytics in Jamaica, Mali, Tanzania, Thailand, Uganda, and Zambia NEW YORK | December 7, 2022 – The Rockefeller Foundation and ...

Sabin Vaccine Institute [to 10 Dec 2022]

<https://www.sabin.org/press/>

Latest News & Press Releases

Press Releases

Sabin Vaccine Institute Delivers Ebola Sudan Vaccine to Fight Outbreak in Uganda

December 8, 2022

Press Releases

Vaccine R&D Leader Kathrin Jansen and Immunologist Kizzmekia Corbett Awarded Sabin's Gold Medal and Rising Star Respectively

December 7, 2022

UNAIDS [to 10 Dec 2022]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

Press statement

International Human Rights Day: ending the AIDS pandemic means respecting human rights for all

GENEVA, 10 December 2022

UNICEF [to 10 Dec 2022]

<https://www.unicef.org/media/press-releases>

Press Releases, News Notes, Statements [Selected]

Press release 05 December 2022

UNICEF appeals for US\$10.3 billion emergency funding to support children affected by conflict, catastrophe and climate crises around the world

<https://www.unicef.org/press-releases/unicef-appeals-us103-billion-emergency-funding-support-children-affected-conflict>

GENEVA/NEW YORK, 5 December 2022 – UNICEF today launched a US\$10.3 billion emergency funding appeal to reach more than 173 million people – including 110 million children – affected by humanitarian crises, the enduring effects of the COVID-19 pandemic worldwide and the growing threat of climate-impacted severe weather events. "Today, there are...

Unitaid [to 10 Dec 2022]

<https://unitaid.org/>

Featured News

09 December 2022

[A record 45 million children accessed seasonal malaria chemoprevention in 2021 thanks to Unitaid's pioneering investments](#)

06 December 2022

[Executive Board approves Unitaid's urgent action to confront antimalarial drug resistance in high burden areas](#)

Vaccine Equity Cooperative [nee Initiative] [to 10 Dec 2022]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 10 Dec 2022]

<https://www.vaccineacceptance.org/>

Announcements, Blog

No new digest content identified.

Vaccine Confidence Project [to 10 Dec 2022]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children's Hospital of Philadelphia [to 10 Dec 2022]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

No new digest content identified.

Wellcome Trust [to 10 Dec 2022]

<https://wellcome.ac.uk/news>

News. Opinion, Reports

No new digest content identified.

The Wistar Institute [to 10 Dec 2022]
<https://www.wistar.org/news/press-releases>

Media

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 10 Dec 2022]
<https://www.wfpfa.org/>

Latest News - Blog

No new digest content identified.

World Medical Association [WMA] [to 10 Dec 2022]
<https://www.wma.net/news-press/press-releases/>

Press Releases

No new digest content identified.

World Organisation for Animal Health (OIE) [to 10 Dec 2022]
<https://www.oie.int/en/>

Press Releases, Statements

No new digest content identified.

.....

ARM [Alliance for Regenerative Medicine] [to 10 Dec 2022]
<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 10 Dec 2022]
<https://www.bio.org/press-releases>

Press Releases

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 10 Dec 2022]
<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 10 Dec 2022]
<https://internationalbiotech.org/news/>

News

No new digest content identified.

IFPMA [to 10 Dec 2022]

<http://www.ifpma.org/resources/news-releases/>

Selected Press Releases, Statements, Publications

Pharmaceutical industry statement delivered at CBD COP 15 meeting regarding Digital Sequence Information and the need for special measures for pathogen sharing

07 December 2022

Pharma industry contributions to third meeting of the Intergovernmental Negotiating Body (INB)

07 December 2022

Impact of a waiver of intellectual property rights for COVID-19 therapeutics

05 December 2022

International Alliance of Patients' Organizations – IAPO [to 10 Dec 2022]

<https://www.iapo.org.uk/news/topic/6>

Press and media [Selected]

No new digest content identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

IGBA joins the Fight the Fakes Alliance (December 2022)

PhRMA [to 10 Dec 2022]

<http://www.phrma.org/>

Press Releases

No new digest content identified.

.....
.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases - *No new digest announcements identified*

Bharat Biotech

Press Releases - *No new digest announcements identified*

BioCubaFarma – Cuba

Últimas Noticias - *Website not responding at inquiry*

Biological E

News - No new digest announcements identified

BioNTech

Press Releases

[**Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza**](#)

9 December 2022

[**Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years**](#)

8 December 2022

[**Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years**](#)

5 December 2022

Boehringer

Press Releases - No new digest announcements identified

CanSinoBIO

News - Website not responding at inquiry

CIGB

Latest News - No new digest announcements identified

Cinnagen

Recent News - No new digest announcements identified

Clover Biopharmaceuticals - China

News - No new digest announcements identified

Curevac [Bayer Ag – Germany]

News - No new digest announcements identified

Gamaleya National Center

Latest News and Events - See Russia above.

GSK

Press releases for media - No new digest announcements identified

IMBCAMS, China

Home - Website not responding at inquiry

Janssen/JNJ

Press Releases - No new digest announcements identified

Medicago

Media - No new digest announcements identified

Merck

News releases - No new digest announcements identified

Moderna

Press Releases

08 December, 2022

[**Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 6 Months Through 5 Years of Age**](#)

Nanogen

News - No new digest announcements identified

Novartis

News - No new digest announcements identified

Novavax

Press Releases

Dec 7, 2022

[**Novavax Nuvaxovid COVID-19 Vaccine Approved in Canada for Use as a Primary Series in Adolescents**](#)

Pfizer

Recent Press Releases

12.08.2022

[**Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years**](#)

12.07.2022

[**U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer's Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults**](#)

12.06.2022

[**Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease**](#)

Agreement aims to advance discovery and development of novel papain-like protease (PLpro) inhibitors and potentially introduce a new class of oral antivirals in the fight against COVID-19

12.05.2022

[**Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years**](#)

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases -- No new digest announcements identified

Serum Institute of India

NEWS & ANNOUNCEMENTS - No new digest announcements identified

Shifa Pharmed [Iran]

<http://shafapharmed.com/>

No news page identified.

Sinopharm/WIBPBIBP

News - No new digest announcements identified

Sinovac

Press Releases

[SINOVAC's Hepatitis A Vaccine Healive® Launched in Indonesia](#)

2022/11/29

SK Biosciences

Press Releases - No new digest announcements identified

Takeda

Newsroom

[Takeda's QDENGAR® \(Dengue Tetravalent Vaccine \[Live, Attenuated\]\) Approved for Use in European Union](#)

December 8, 2022

Valneva

Press Releases

December 5, 2022

[Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate](#)

Vector State Research Centre of Virology and Biotechnology

Home - Website not responding [404 error]

WestVac Biopharma

Media

[Recombinant COVID-19 Vaccine - Covaccine Developed by WestVac Biopharma/West China Hospital of Sichuan University Approved for Emergency Use](#)

2022-12-05

Recently, the Recombinant COVID-19 Vaccine (Sf9 cell) - Covaccine developed by WestVac Biopharma Co., Ltd./West China Hospital of Sichuan University was approved by the relevant state authorities for emergency use, contributing to the prevention and control of the COVID-19 in China and the rest of the world. This is also the first insect cell-expressed Recombinant COVID-19 Vaccine approved for emergency use in China.

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

.....
.....

Contents [click to move among sections]

:: [*Coronavirus \[COVID-19\] - WHO*](#)
:: [*Organization Announcements*](#)
:: [*Journal Watch*](#)
:: [*Pre-Print Servers*](#)

.....
.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 13, 2022 Issue 4
<https://www.tandfonline.com/toc/uabr21/current>
[Reviewed earlier]

AMA Journal of Ethics

Volume 24, Number 12: E1107-1182
<https://journalofethics.ama-assn.org/issue/stillness-and-solidarity>

With Stillness and Solidarity

This issue considers stillness and solidarity as necessary to orientating oneself to health care practice and professionalism. These two are both actions and virtues, which enable students' and clinicians' transformation from bystanders to upstanders. Stillness is conceived herein as intentional discipline applied to creating deliberate, restorative spatial and temporal interruption from day-to-day demands in order to nourish the moral motivational generosity needed to care well for patients and to be good colleagues. Solidarity is conceived herein as requiring deliberate nourishing in health professions education and work environments, such that slowing down, a necessary precedent set of actions to becoming still, can be robustly achieved and engaged. This issue explores ways in which solidarity can be considered less as a set of political actions of single individuals and more as a collective organizational and professional capacity for responding with care to both our unique and common vulnerabilities.

[Reviewed earlier]

American Journal of Infection Control

December 2022 Volume 50 Issue 12 p1281-1400

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

December 2022 Volume 63 Issue 6p 875-1064

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

December 2022 112(12)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 107 (2022): Issue 5 (Nov 2022)

<https://www.ajtmh.org/view/journals/tpmd/107/5/tpmd.107.issue-5.xml>

[Reviewed earlier]

Annals of Internal Medicine

November 2022 Volume 175, Issue 11

<http://annals.org/aim/issue>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 313 December 2022

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/313/suppl/C>

[New issue; No digest content identified]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 10 Dec 2022)

[No new digest content identified]

BMJ Global Health

November 2022 - Volume 7 - 11

<https://gh.bmj.com/content/7/11>

[Reviewed earlier]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 10 Dec 2022)

The development and validation of a novel COVID19 stigma scale among healthcare workers (COVISS-HCWs)

Fear of coronavirus disease 2019 (COVID-19) and its complications may result in stigmatization of individuals who may carry the virus. This is of special concern to healthcare workers who tolerate additional p...

Authors: Hasan Nabil Al Hourri, Abdullah Alhourri, Rand T. Akasheh, Christine E. S. Jovanovic, Heba Al-tarcheh, Douaa Mohammad Nazir Arrouk, Ahmad Nabil Alhourri, Marah Marrawi, Malik E. Juweid and Youssef Latifeh

Citation: BMC Health Services Research 2022 22:1481

Content type: Research Published on: 5 December 2022

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 10 Dec 2022)

Pneumococcal concentration and serotype distribution in preschool children with radiologically confirmed pneumonia compared to healthy controls prior to introduction of pneumococcal vaccination in Zanzibar: an observational study

The World Health Organization recommends pneumococcal vaccination (PCV) in the first year of life. We investigated pneumococcal serotypes in children with clinical or radiologically confirmed pneumonia and hea...

Authors: Kristina Elfving, Lucia Gonzales Strömberg, Shadi Geravandi, Maria Andersson, Marc Bachelard, Mwinyi Msellem, Delér Shakely, Birger Trollfors, Rickard Nordén, Andreas Mårtensson, Anders Björkman and Magnus Lindh

Citation: BMC Infectious Diseases 2022 22:925

Content type: Research Published on: 10 December 2

Effectiveness of seasonal influenza vaccine in elementary and middle schools: a 10-year follow-up investigation

Influenza spreads from schools to the rest of society. Thus, we conducted questionnaire surveys of influenza vaccination in elementary and middle schools in a district for 10 years to determine immunization ra...

Authors: Teruyuki Kajiume, Sumera Mukai, Nobutaka Toyota, Ikuo Kanazawa, Akiko Kato, Etsushi Akimoto and Toshio Shirakawa

Citation: BMC Infectious Diseases 2022 22:909

Content type: Research article Published on: 6 December 2022

Five consecutive epidemiological waves of COVID-19: a population-based cross-sectional study on characteristics, policies, and health outcome

This study was conducted with the intension of providing a more detailed view about the dynamics of COVID-19 pandemic. To this aim, characteristics, implemented public health measures, and health outcome of CO...

Authors: Rozhin Amin, Mohammad-Reza Sohrabi, Ali-Reza Zali and Khatereh Hannani

Citation: BMC Infectious Diseases 2022 22:906

Content type: Research Published on: 5 December 2022

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 10 Dec 2022)

Extended essay

COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities

Kevin Bardosh, et al.

Abstract

In 2022, students at North American universities with third-dose COVID-19 vaccine mandates risk disenrolment if unvaccinated. To assess the appropriateness of booster mandates in this age group, we combine empirical risk-benefit assessment and ethical analysis. To prevent one COVID-19 hospitalisation over a 6-month period, we estimate that 31 207–42 836 young adults aged 18–29 years must receive a third mRNA vaccine. Booster mandates in young adults are expected to cause a net harm: per COVID-19 hospitalisation prevented, we anticipate at least 18.5 serious adverse events from mRNA vaccines, including 1.5–4.6 booster-associated myopericarditis cases in males (typically requiring hospitalisation). We also anticipate 1430–4626 cases of grade ≥ 3 reactogenicity interfering with daily activities (although typically not requiring hospitalisation). University booster mandates are unethical because they: (1) are not based on an updated (Omicron era) stratified risk-benefit assessment for this age group; (2) may result in a net harm to healthy young adults; (3) are not proportionate: expected harms are not outweighed by public health benefits given modest and transient effectiveness of vaccines against transmission; (4) violate the reciprocity principle because serious vaccine-related harms are not reliably compensated due to gaps in vaccine injury schemes; and (5) may result in wider social harms. We consider counterarguments including efforts to increase safety on campus but find these are fraught with limitations and little scientific support. Finally, we discuss the policy relevance of our analysis for primary series COVID-19 vaccine mandates.

Assent, parental consent and re consent for health research in Africa: thematic analysis of national guidelines and lessons from the SickleInAfrica registry

The enrolment of children and adolescents in health research requires that attention to be paid to specific assent and consent requirements such as the age range for seeking assent; conditions for parental con...

Authors: Nchangwi Syntia Munung, Victoria Nembaware, Lawrence Osei-Tutu, Marsha Treadwell, Okocha Emmanuel Chide, Daima Bukini, Hilda Tutuba and Ambroise Wonkam

Citation: BMC Medical Ethics 2022 23:130

Content type: Research Published on: 8 December 2022

Children as an afterthought during COVID-19: defining a child-inclusive ethical framework for pandemic policymaking

Following the SARS pandemic, jurisdictions around the world began developing ethical resource allocation frameworks for future pandemics—one such framework was developed by Thompson and colleagues. While this ...

Authors: Sydney Campbell and Franco A. Carnevale

Citation: BMC Medical Ethics 2022 23:126

Content type: Debate Published on: 5 December 2022

Guardians and research staff experiences and views about the consent process in hospital-based paediatric research studies in urban Malawi: A qualitative study

Obtaining consent has become a standard way of respecting the patient's rights and autonomy in clinical research. Ethical guidelines recommend that the child's parent/s or authorised legal guardian provides in...

Authors: Mtisunge Joshua Gondwe, Neema Mtunthama Toto, Charity Gunda, Markus Gmeiner, Ian J. C. McCormick, David Laloo, Michael Parker and Nicola Desmond

Citation: BMC Medical Ethics 2022 23:125

Content type: Research article Published on: 5 December 2022

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 10 Dec 2022)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 10 Dec 2022)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 10 Dec 2022)

The influence of social class and institutional relationships on the experiences of vaccine-hesitant mothers: a qualitative study

Vaccine hesitancy is a growing problem in the United States. However, our understanding of the mechanisms by which socioeconomic status (SES) shapes the experience of vaccine hesitancy and decision-making is i...

Authors: Lindsay W. Glassman and Julia E. Szymczak

Citation: BMC Public Health 2022 22:2309

Content type: Research Published on: 9 December 2022

COVID-19 vaccination acceptance in underserved urban areas of Islamabad and Rawalpindi: results from a cross-sectional survey

Urban slums are home to a significant number of marginalized individuals and are often excluded from public services. This study explores the determinants of willingness and uptake of COVID-19 vaccines in urba...

Authors: Twangar Kazmi, Mujahid Abdullah, Adnan Ahmad Khan, Rana Muhammad Safdar, Sabeen Afzal and Ayesha Khan

Citation: BMC Public Health 2022 22:2299

Content type: Research Published on: 8 December 2022

Excess mortality and the COVID-19 pandemic: causes of death and social inequalities

During the coronavirus diseases 2019 (COVID-19) pandemic, population's mortality has been affected not only by the risk of infection itself, but also through deferred care for other causes and changes in lives...

Authors: Jieun Oh, Jieun Min, Cino Kang, Ejin Kim, Jung Pyo Lee, Ho Kim and Whanhee Lee

Citation: BMC Public Health 2022 22:2293

Content type: Research Published on: 7 December 2022

Knowledge of cervical cancer prevention and treatment, and willingness to receive HPV vaccination among college students in China

Cervical cancer is the fourth most common cancer in women. Up to 99% of cervical cancer cases are associated with high-risk human papillomavirus (HPV). Sexual behavior is a direct risk factor for HPV infection...

Authors: Fengzhi Zhang, Manman Li, Xiaoxue Li, Hua Bai, Jinling Gao and Hua Liu

Citation: BMC Public Health 2022 22:2269

Content type: Research Published on: 5 December 2022

Assessing barriers to access and equity for COVID-19 vaccination in the US

Historical vaccination coverage in economically disadvantaged, ethnic minority, non-affluent white and agricultural populations in the US has lagged coverage in more affluent urban and suburban white populatio...

Authors: Michael Kuehn, Joyce LaMori, Jessica K. DeMartino, Marco Mesa-Frias, Jason Doran, Lohit Korrapati, Rhea Bhojwani, Patrick Lefebvre and Noam Kirson

Citation: BMC Public Health 2022 22:2263

Content type: Research Published on: 3 December 2022

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 10 Dec 2022)

[No new digest content identified]

BMJ Evidence-Based Medicine

December 2022 - Volume 27 - 6

<https://ebm.bmj.com/content/27/6>

[Reviewed earlier]

BMJ Open

November 2022 - Volume 12 - 11

<https://bmjopen.bmj.com/content/12/11>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 100(12); 2022 Dec 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/422466/>

[Reviewed earlier]

Cell

Dec 08, 2022 Volume 185 Issue 25 p4675-4862

<https://www.cell.com/cell/current>

Featured Article

Immune cell interactions in tuberculosis

JoAnne L. Flynn, John Chan

Tuberculosis is an infectious disease affecting millions worldwide. The causative pathogen, *Mycobacterium tuberculosis* deploys multiple mechanisms to evade host immune responses, thus challenging the development of an effective vaccine. This review highlights the importance of understanding immune cells in tuberculosis in a holistic manner to better achieve protective immunity.

Child Care, Health and Development

Volume 48, Issue 6 Pages: 881-1137 November 2022

<https://onlinelibrary.wiley.com/toc/13652214/current>

Special Issue: The Pervasive Effects of COVID-19 on Children: A Global Perspective

Issue Edited by: Jan Willian Gorter, Evelyn Culnane, Lyndal Hickey, Mark Ferro, Tony Okely

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 112, Issue 6 Pages: 1131-1339 December 2022

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

Editorial Free Access

How a Pandemic Simultaneously Strengthened Existing Fundamentals and Drove New Innovations in Clinical Pharmacology

Shirley K. Seo, Piet H. van der Graaf

Pages: 1141-1144

First Published: 19 November 2022

Reviews Open Access

The Current Landscape and Emerging Applications for Real-World Data in Diagnostics and Clinical Decision Support and its Impact on Regulatory Decision Making

Elodie Baumfeld Andre, Nate Carrington, Flora S. Siami, Jo Carol Hiatt, Carly McWilliams, Carolyn Hiller, Andy Surinach, Alejandro Zamorano, Chris L. Pashos, Wade L. Schulz

Pages: 1172-1182

First Published: 25 February 2022

Assessing the Combined Public Health Impact of Pharmaceutical Interventions on Pandemic Transmission and Mortality: An Example in SARS CoV-2

Mohamed A. Kamal, Andreas Kuznik, Luyuan Qi, Witold Więcek, Mohamed Hussein, Hazem E. Hassan, Kashyap Patel, Thomas Obadia, Masood Khaksar Toroghi, Daniela J. Conrado, Nidal Al-Huniti, Roman Casciano, Meagan P. O'Brien, Ruanne V. Barnabas, Myron S. Cohen, Patrick F. Smith

Pages: 1224-1235

First Published: 19 August 2022

Clinical Therapeutics

November 2022 Volume 44 Issue 11 p1427-1548

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 19 Issue 6, December 2022

<https://journals.sagepub.com/toc/ctja/19/6>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 10 Dec 2022]

[No new digest content identified]

Contemporary Clinical Trials

Volume 123 December 2022

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/123/suppl/C>

Patient Recruitment

Short communication Abstract only

[Using plain language to communicate with clinical trials participants: Comparison of readability calculators](#)

Lauren McGrath, Beverley C. Millar, John E. Moore

Article 106995

Abstract

It is important that patient-facing clinical trial information is easily understood by potential trial participants, active trial participants, family members, friends and carers. The readability of a document refers to its typographic and linguistic characteristics that allow the text to be read and comprehended and it is recommended that healthcare providers aim that all information disseminated to the lay public be at a suitable readability level. Whilst there are established readability calculators for literature, there is no standard for health information. Several readability calculators are available that aid in the analysis of a text, URL or website's readability, however, to date there has been no head-to-head comparison of these. Five readability calculators were compared, including four online realtime calculators, (i) Readable (www.readable.com), (ii) www.webfx.com, (iii) www.datayze.com and (iv) www.online-utility.org, as well as the PC-based analyzer Microsoft Word (Microsoft Corp., USA). Three categories of text information were analysed, including (i) childrens' fairy tales (n = 20) (ii) scientific reports (n = 20) from BBC News websites and (iii) scientific abstracts (n = 20). This study demonstrated that varying scores were obtained by using different readability calculators. Based on these data in combination with issues including availability and ease-of-use, we advocate the use of Readable or Microsoft Word software to aid in the preparation of patient-facing clinical trial information. Clinical trial networks should now consider the need for standardisation of readability calculators and provide guidance to stakeholders so that readability of materials may be improved in a standardised and uniform manner.

The CRISPR Journal

Volume 5, Issue 5 / October 2022

<https://www.liebertpub.com/toc/crispr/5/5>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 10, issue 3, September 2022

<https://link.springer.com/journal/40142/volumes-and-issues/10-3>

[Reviewed earlier]

Current Opinion in Infectious Diseases

December 2022 - Volume 35 - Issue 6

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>

[Reviewed earlier]

Developing World Bioethics

Volume 22, Issue 4 Pages: 181-299 December 2022

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 32, Issue 8, 2022

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 16 - Issue 5 - October 2022

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 47, Issue 1 Pages: 1-244 January 2023

<https://onlinelibrary.wiley.com/toc/14677717/current>

[New issue; No digest content identified]

EMBO Reports

Volume 23 Issue 12 6 December 2022

<https://www.embopress.org/toc/14693178/current>

Opinion 14 November 2022 Free to Read

[Scholars in peril: when being a scientist can land you in jail \(or worse\)](#)

Shina Caroline Lynn Kamerlin

The scientific community needs to speak up loudly to support colleagues who are persecuted and imprisoned for political reasons.

Emerging Infectious Diseases

Volume 28, Number 12—December 2022

<http://wwwnc.cdc.gov/eid/>

Synopses

[Probable Aerosol Transmission of SARS-CoV-2 through Floors and Walls of Quarantine Hotel, Taiwan, 2021 \[PDF - 2.81 MB - 9 pages\]](#)

H. Wei et al.

Research

[Association between Conflict and Cholera in Nigeria and the Democratic Republic of the Congo \[PDF - 3.77 MB - 10 pages\]](#)

G. Charnley et al.

Epidemics

Volume 41 December 2022

<https://www.sciencedirect.com/journal/epidemics/vol/41/suppl/C>

Research article Open access

[The role of public involvement in the design of the first SARS-CoV-2 human challenge study during an evolving pandemic](#)

Maria Piggan, Emma Smith, Peter Mankone, Leah Ndegwa, ... Caroline Barker

Article 100626

Highlights

- Public involvement informed the design of a SARS-CoV-2 human challenge study.
- Discussions supported decision making around study exclusion criteria.
- Study materials and consent processes were changed following public review.
- The public were concerned for the wellbeing of participants.
- Human challenge studies were seen as efficient and fast.
- Public insights supported ethical review of the study.

Research article Open access

[Impact of disruptions to routine vaccination programs, quantifying burden of measles, and mapping targeted supplementary immunization activities](#)

Natalya Kostandova, Stacie Loiate, Amy Winter, William J. Moss, ... Amy Wesolowski

Article 100647

Research article Open access

Considering equity in priority setting using transmission models: Recommendations and data needs

M. Quaife, GF Medley, M. Jit, T. Drake, ... GB Gomez

Article 100648

Research article Open access

In the shadow of privacy: Overlooked ethical concerns in COVID-19 digital epidemiology

Agata Ferretti, Effy Vayena

Article 100652

Highlights

- Digital epidemiology holds great potential to surveil and fight epidemics.
- Privacy monopolizes the debate on the ethics and governance of digital epidemiology.
- Other important issues and their ethical consequences remain unaddressed.
- Overlooking these issues will undermine the power of health surveillance technology.
- Need for a broader ethical approach and a social license for data uses.

Epidemiology and Infection

Volume 150 - 2022

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 44, Issue 6 Pages: 1-42 November–December 2022

<https://onlinelibrary.wiley.com/toc/25782363/current>

Alzheimer disease biomarkers :: Payment to participate

[Reviewed earlier]

Ethics & International Affairs

Summer 2022 (36.2) | July 29, 2022

<https://www.ethicsandinternationalaffairs.org/2022/summer-2022-36-2/>

ROUNDTABLE: VULNERABLE COMMUNITIES, FUTURE GENERATIONS, AND POLITICAL REPRESENTATION IN CLIMATE POLICY AND PRACTICE

... This roundtable collection is motivated by the following question: How can the voices of vulnerable communities and future generations be adequately and fairly represented within climate change policy and practice? The contributions address this question from several perspectives. Simon Caney focuses on global governance institutions to protect the interests of future generations, considering specific proposals and asking what criteria should be used to evaluate them. Stephen Gardiner's essay builds on his previous work calling for a global constitutional convention, elaborating on the proposal and addressing objections to it. Colin Hickey argues that it is necessary to consider more informal modes of representing vulnerable communities and future generations, such as through grassroots organizations. In our contribution, we argue that the interests of future generations are best represented in deliberations around climate policy and practice by those already most vulnerable to the impacts of climate change. Marco Grix and Krushil Watene's essay argues that the representation of climate-

vulnerable communities and future generations—in particular, Indigenous peoples—must ensure the protection of the complex network of social practices that guide how vulnerable communities respond to climate change...

Ethics, Medicine and Public Health

Volume 25 December 2022

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/25/suppl/C>

Editorial

Praise of a medical and public health ethics for the 21st century

C. Herve, P. Charlier

Article 100286

Beyond Covid-19, why AI is revolutionizing the scientific ecosystem

C. Bommier, J. Haiech, P. Charlier, DALL-E2, DaVinci-002

Article 100853

The European Journal of Public Health

Volume 32, Issue 6, December 2022

<https://academic.oup.com/eurpub/issue/32/6>

Editorials

'Disease X'—time to act now and prepare for the next pandemic threat

Daniele Mipatrini, Chiara Montaldo, Barbara Bartolini, Giovanni Rezza, Sergio Iavicoli ...

Covid-19

Media use and trust during the COVID-19 pandemic: evidence from eight cross-sectional surveys in Sweden

Maike Winters, Olivia Biermann, Gustav Bohlin, Martin Bergman, Fredrik Brounéus ...

European Journal of Public Health, Volume 32, Issue 6, December 2022, Pages 976–981,

Electoral and religious correlates of COVID-19 vaccination rates in Dutch municipalities

Alexandre Afonso, Fabio Votta

European Journal of Public Health, Volume 32, Issue 6, December 2022, Pages 985–987,

<https://doi.org/10.1093/eurpub/ckac112>

Expert Review of Vaccines

Vol 21 (12) 2022

<https://www.tandfonline.com/toc/ierv20/current>

Editorial

Influence of social media on the public perspectives of the safety of COVID-19 vaccines

Sai Krishna Gudi, Sophia M. George & Jimmy Jose

Pages: 1697-1699

Published online: 12 Apr 2022

Article

The value of public-private collaborative real-world evidence platforms to monitor vaccine performance post authorization: DRIVE - a European initiative

Javier Díez-Domingo, Laurence Torcel-Pagnon, Antonio Carmona, Odile Launay, Gaël Dos Santos, Caterina Rizzo, Mendel Haag, Anke Stuurman, Jos Nauta, Alfredo Vannacci, Simon de Lusignan, Elena Del Rey, Miriam Levi, Bruno Lina, Stefania Bellino, Samantha Nye, Pieter Neels, Hanna Nohynek & Cédric Mahéon behalf of the DRIVE consortium

Pages: 1701-1710

Published online: 27 Oct 2022

Review

Modern vaccine strategies for emerging zoonotic viruses

Atif Ahmed, Muhammad Safdar, Samran Sardar, Sahar Yousaf, Fiza Farooq, Ali Raza, Muhammad Shahid, Kausar Malik & Samia Afzal

Pages: 1711-1725

Published online: 27 Nov 2022

Review

Success of nano-vaccines against COVID-19: a transformation in nanomedicine

Manoj Kumar Sarangi, Sasmita Padhi, Gautam Rath, Sitansu Sekhar Nanda & Dong Kee Yi

Pages: 1739-1761

Published online: 27 Nov 2022

Review

Real-world impact and effectiveness of the quadrivalent HPV vaccine: an updated systematic literature review

Wei (Vivian) Wang, Smita Kothari, Jozica Skufca, Anna R. Giuliano, Karin Sundström, Mari Nygård, Carol Koro, Marc Baay, Thomas Verstraeten, Alain Luxembourg, Alfred J. Saah & Suzanne M. Garland

Pages: 1799-1817

Published online: 04 Nov 2022

Meta-analysis

Effectiveness of vaccination against SARS-CoV-2 Omicron variant infection, symptomatic disease, and hospitalization: a systematic review and meta-analysis

Angela Meggiolaro, Monica Sane Schepisi, Sara Farina, Carolina Castagna, Alessia Mammone, Andrea Siddu, Paola Stefanelli, Stefania Boccia & Giovanni Rezza

Pages: 1831-1841

Published online: 14 Oct 2022

Article

The impact of vaccination on the burden of invasive pneumococcal disease from a nationwide surveillance program in Lebanon: an unexpected increase in mortality driven by non-vaccine serotypes

Lina Reslan, Nour Youssef, Celina F. Boutros, Aia Assaf-Casals, Danielle Fayad, Sarah Khafaja, Fata Akl, Marc Finianos, Amena A. Rizk, Rouba Shaker, Alissar Zaghlout, Mireille Lteif, Bassam El Hafi, Mohammad Bahij Moumneh, Rita Feghali, Soha Ghanem, Tamima Jisr, Gilbert Karayakoupoglou, Malak Naboulsi, Monzer Hamze, Salam Samad, Elie Khoury, Ricardo Sarraf, Marwan Osman, Elie Bou Raad, Hadi El Amin, Ibrahim Abadi, Hicham Abdo, Marwan Chedid, Fatima Chamseddine, Angelique Barakat, Mohammad Houmani, Antoine Haddad, Georges Abdel Nour, Jacques E. Mokhbat, Ziad Daoud,

Mohamad El-Zaatari, Elie Salem Sokhn, Nada Ghosn, Walid Ammar, Randa Hamadeh, Ghassan M. Matar, George F. Araj & Ghassan S. Dbaibo for the Lebanese Inter-Hospital Pneumococcal Surveillance Program investigators
Pages: 1905-1921
Published online: 17 Nov 2022

Foreign Affairs

Volume 101, Number 6 November/December 2022
<https://www.foreignaffairs.com/issues/2022/101/6>
[New issue; No digest content identified]

Forum for Development Studies

Volume 49, 2022 - Issue 3
<http://www.tandfonline.com/toc/sfds20/current>
[Reviewed earlier]

Genetics in Medicines

Volume 24, Issue 12 Pages A1-A8, 2419-2598 (December 2022)
<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/24/issue/12>
Research article Open access
[**Awareness and use of genetic testing: An analysis of the Health Information National Trends Survey 2020**](#)
Jessica C. Tiner, Leah E. Mechanic, Lisa Gallicchio, Elizabeth M. Gillanders, Kathy J. Helzlsouer
Pages 2526-2534

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>
[Accessed 10 Dec 2022]
[No new digest content identified]

Global Health Action

Volume 15, Issue 1 (2022)
<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>
[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 10, No. 5 October 31, 2022
<http://www.ghspjournal.org/content/current>
[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>
[Accessed 10 Dec 2022]
[No new digest content identified]

Global Public Health

Volume 17, Issue 11 (2022)
<http://www.tandfonline.com/toc/rqph20/current>
[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>
[Accessed 10 Dec 2022]

[Bridging the genomic data gap in Africa: implications for global disease burdens](#)

This paper highlights the gap in the use of genomic data of Africans for global research efforts for disease cures. Genomic data represents an important tool used in disease research for understanding how disease...

Authors: Olabode Ebenezer Omotoso, John Oluwafemi Teibo, Festus Adebayo Atiba, Tolulope Oladimeji, Ayomide Oluwadarasimi Adebessin and Ahmad O. Babalghith

Citation: Globalization and Health 2022 18:103

Content type: Review Published on: 9 December 2022

Health and Human Rights

Volume 24, Issue 1, June 2022
<https://www.hhrjournal.org/volume-24-issue-1-june-2022/>
[Reviewed earlier]

Health Economics, Policy and Law

Volume 17 - Issue 4 - October 2022
<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>
[Reviewed earlier]

Health Policy and Planning

Volume 37, Issue 9, November 2022
<https://academic.oup.com/heapol/issue/37/9>
[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>
[Accessed 10 Dec 2022]
[No new digest content identified]

Human Gene Therapy

Volume 33, Issue 21-22 / November 2022

<https://www.liebertpub.com/toc/hum/33/21-22>

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

Featured Publications

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 18, Issue 5, 2022

<https://www.tandfonline.com/toc/khvi20/18/5?nav=tocList>

[Reviewed earlier]

Immunity

Nov 08, 2022 Volume 55 Issue 11 p1967-2210

<https://www.cell.com/immunity/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 10 Dec 2022]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>

[Accessed 10 Dec 2022]

[No new digest content identified]

International Health

Volume 14, Issue 6, November 2022

<https://academic.oup.com/inthealth/issue/14/6>

[Reviewed earlier]

International Human Rights Law Review

Volume 11 (2022): Issue 1 (Jun 2022)

<https://brill.com/view/journals/hrlr/11/1/hrlr.11.issue-1.xml>

Table of Contents

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol 9, No 11 (2022) November 2022

<https://www.ijcmph.com/index.php/ijcmph/issue/view/94>

[New issue; No digest content identified]

International Journal of Epidemiology

Volume 51, Issue 5, October 2022

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 15 Issue 3, 2022

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/15/iss/3>

Special Issue: Children, young people and their international human right to healthcare

[Reviewed earlier]

JAMA

December 6, 2022, Vol 328, No. 21, Pages 2085-2170

<https://jamanetwork.com/journals/jama/currentissue>

[New issue; No digest content identified]

JAMA Pediatrics

December 2022, Vol 176, No. 12, Pages 1160-1276

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

Original Investigation

[Effect of Wearing a Face Mask on Hand-to-Face Contact by Children in a Simulated School Environment](#)
[The Back-to-School COVID-19 Simulation Randomized Clinical Trial](#)

Michelle Science, MD, MSc; Monica Caldeira-Kulbakas, PhD; Rulan S. Parekh, MD, MSc, FRCPC; et al.
open access has active quiz

JAMA Pediatr. 2022;176(12):1169-1175. doi:10.1001/jamapediatrics.2022.3833

This randomized clinical trial evaluates the effect of wearing a face mask on hand-to-face contact by children while at school.

Special Communication

[Reimagining Children's Rights in the US](#)

Elizabeth Barnert, MD, MPH, MS; Joseph Wright, MPH, MS; Charlene Choi, JD; et al.
has active quiz

JAMA Pediatr. 2022;176(12):1242-1247. doi:10.1001/jamapediatrics.2022.3822

This Special Communication discusses the potential ways in which the US can advance children's rights through the adoption of a children's rights framework and the implementation of a children's rights approach to benefit and protect children's health and well-being.

Importance The US faces a pivotal moment of opportunity and risk regarding issues affecting children (aged 0-17 years). Although the US remains the only United Nations member state to not have

ratified the Convention on the Rights of the Child (CRC), a child rights framework is essential for child health professionals seeking to advance many issues affecting children in the US. The Reimagining Children's Rights project (2020-2021) conducted an in-depth environmental scan of relevant literature and policy analysis using the Three Horizons design process to assess strategies that could advance the rights and well-being of children in the US. The project was overseen by a steering committee and informed by an advisory committee composed of youth leaders and experts in children's rights, advocacy, health, law, and a range of child-specific issues (eg, youth justice, early childhood development), who provided expert input on strategic considerations for advancing children's rights.

JBIR Evidence Synthesis

November 2022 - Volume 20 - Issue 11

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

December 2022 Volume 71 Issue 6 p655-772

<https://www.jahonline.org/current>

Original Articles

Parents' Acceptance of COVID-19 Compared to Human Papillomavirus Vaccines

Alison Footman, et al.

Published online: October 05, 2022

p673-678

Journal of Artificial Intelligence Research

Vol. 75 (2022)

<https://www.jair.org/index.php/jair>

Contents

[Reviewed earlier]

Journal of Community Health

Volume 47, issue 6, December 2022

<https://link.springer.com/journal/10900/volumes-and-issues/47-6>

[Reviewed earlier]

Journal of Development Economics

Volume 160 January 2023

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/160/suppl/C>

[New issue; No digest content identified]

Journal of Empirical Research on Human Research Ethics

Volume 17 Issue 5, December 2022

<http://journals.sagepub.com/toc/jre/current>

Ethical Issues using Digital Surveillance Technologies in Research

[Reviewed earlier]

Journal of Epidemiology & Community Health

December 2022 - Volume 76 - 12

<https://jech.bmj.com/content/76/12>

Commentaries

[Global inequity of COVID-19 diagnostics: challenges and opportunities](#) (6 October, 2022)

Shanti Narayanasamy, Brenda Okware, Winters Muttamba, Kirtika Patel, Kwabena Obeng Duedu, Nirmal Ravi, Nathan Ellermeier, Muki Shey, Christopher W Woods, Wilber Sabiti

Journal of Evidence-Based Medicine

Volume 15, Issue 3 Pages: 181-314 September 2022

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 18, Issue 2, 2022

<http://www.tandfonline.com/toc/rjge20/current>

Symposium

Article

[A neo-feudal world order? Introduction to the symposium on Peter Hägel's Billionaires in World Politics](#)

Julian Culp

Pages: 196-200

Published online: 29 Nov 2022

Research Article

[Billionaires in world politics: donors, governors, authorities](#)

Klaus Dingwerth & Julian Eckl

Pages: 201-210

Published online: 29 Nov 2022

Article

[The democratic deficit of the G20](#)

Sören Hilbrich

Pages: 248-266

Published online: 10 Oct 2021

Article

[The right to immigrate and responsibility for the past](#)

Michael Rabinder James

Pages: 267-285

Published online: 17 Jun 2022

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 33, Number 4, November 2022

<https://muse.jhu.edu/issue/48371>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 24, issue 6, December 2022

<https://link.springer.com/journal/10903/volumes-and-issues/24-6>

Contents

[The Impact of a Comic Book Intervention on East African-American Adolescents' HPV Vaccine-Related Knowledge, Beliefs and Intentions](#)

Authors (first, second and last of 12)

Michelle B. Shin, et al.

Content type: Original Paper

Published: 31 March 2022

Pages: 1489 - 1500

Journal of Immigrant & Refugee Studies

Volume 20, 2022 _ Issue 4

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 226, Issue 10, 15 November 2022

<https://academic.oup.com/jid/issue/226/10>

[Reviewed earlier]

Journal of International Development

Volume 34, Issue 8 Pages: 1453-1648 November 2022

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Medical Ethics

December 2022 - Volume 48 - 12

<http://jme.bmj.com/content/current>

Current controversies

[Vaccine passports and health disparities: a perilous journey](#) (9 July, 2021) Free

Nancy S Jecker

Original research

Public attitudes about equitable COVID-19 vaccine allocation: a randomised experiment of race-based versus novel place-based frames (4 August, 2022)

Harald Schmidt, Sonia Jawaid Shaikh, Emily Sadecki, Alison Buttenheim, Sarah Gollust

Accessing unproven interventions in the COVID-19 pandemic: discussion on the ethics of 'compassionate therapies' in times of catastrophic pandemics (13 October, 2021) Free

Shlomit Zuckerman, Yaron Barlavie, Yaron Niv, Dana Arad, Shaul Lev

How low can you go? Justified hesitancy and the ethics of childhood vaccination against COVID-19 (25 February, 2022)

Stephen David John

Journal of Patient-Centered Research and Reviews

Volume 9, Issue 3 (2022)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

Journal of Pediatrics

November 2022 Volume 250 p1-118

<http://www.jpeds.com/current>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>

[Accessed 10 Dec 2022]

[No new digest content identified]

Journal of Public Health Management & Practice

November/December 2022 - Volume 28 - Issue 6

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 43, issue 3, September 2022

<https://link.springer.com/journal/41271/volumes-and-issues/43-3>

[Reviewed earlier]

Journal of Refugee & Global Health

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

Journal of the Royal Society – Interface

December 2022 Volume 19 Issue 197

<https://royalsocietypublishing.org/toc/rsif/current>

[New issue; No digest content identified]

Journal of Travel Medicine

Volume 29, Issue 7, October 2022

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 96 Number 18 September 2022

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Dec 10, 2022 Volume 400 Number 10368 p2007-2154, e13

<https://www.thelancet.com/journals/lancet/issue/current>

Editorial

[Advancing racial and ethnic equity in health](#)

The Lancet

Series

Racism, Xenophobia, Discrimination, and Health

[Executive summary](#)

Delan Devakumar, et al.

[Racism, xenophobia, discrimination, and the determination of health](#)

Delan Devakumar, et al.

[Racism, xenophobia, and discrimination: mapping pathways to health outcomes](#)

Sujitha Selvarajah, et al.

[Intersectional insights into racism and health: not just a question of identity](#)

Geordan Shannon, et al.

[Confronting the consequences of racism, xenophobia, and discrimination on health and health-care systems](#)

Ibrahim Abubakar, et al.

The Lancet Child & Adolescent Health

Dec 2022 Volume 6 Number 12 p829-894, e24-e28

<https://www.thelancet.com/journals/lanchi/issue/current>

Comment

Ethical artificial intelligence in paediatrics

Samantha Boch, Emre Sezgin, Simon Lin Linwood

The use of artificial intelligence (AI) in paediatric research and clinical practice has steadily increased and has mostly been leveraged to augment diagnostic assessment, risk prediction, and treatment of specific child health conditions.¹ Yet, AI efforts focused on health equity are limited to the adult population² or early-life adversities due to environmental exposures.³ In paediatrics, AI could aid providers and systems in understanding and mitigating social risk, and nurturing more equitable care.⁴

Lancet Digital Health

Dec 2022 Volume 4 Number 12 e850-e905

<https://www.thelancet.com/journals/landig/issue/current>

[New issue; No digest content identified]

Lancet Global Health

Dec 2022 Volume 10 Number 12 e1688-e1866

<https://www.thelancet.com/journals/langlo/issue/current>

Comment

Seasonal targeting of the RTS,S/AS01 malaria vaccine: a complementary tool but sustained funding is required

Sheetal Prakash Silal

Effectiveness of a new vaccine for outbreak response and the increasingly complicated polio endgame

Kimberly M Thompson

Articles

Assessing performance of the Healthcare Access and Quality Index, overall and by select age groups, for 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019

GBD 2019 Healthcare Access and Quality Collaborators

Global impact of COVID-19 on childhood tuberculosis: an analysis of notification data

Lasith Ranasinghe, et al.

Seasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study

Hayley A Thompson, et al.

Viewpoint

Ethics and governance challenges related to genomic data sharing in southern Africa: the case of SARS-CoV-2

Keymanthri Moodley, et al.

Lancet Infectious Diseases

Dec 2022 Volume 22 Number 12 p1649-1770, e348-e381

<https://www.thelancet.com/journals/laninf/issue/current>

Editorial

[Why hybrid immunity is so triggering](#)

The Lancet Infectious Diseases

Comment

[Evaluating novel COVID-19 vaccines in the current chapter of the pandemic](#)

Corine H GeurtsvanKessel, Rory D de Vries

Articles

[Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 \(ENSEMBLE2\): results of a randomised, double-blind, placebo-controlled, phase 3 trial](#)

Karin Hardt, et al. for the ENSEMBLE2 study group

[Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine \(VLA2001\) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK \(COV-COMPARE\): interim analysis of a randomised, controlled, phase 3, immunobridging trial](#)

Rajeka Lazarus, et al on behalf of the Valneva phase 3 trial group

[Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial](#)

Mehreen S Datoo, et al.

[Waning of antibody levels induced by a 13-valent pneumococcal conjugate vaccine, using a 3 + 0 schedule, within the first year of life among children younger than 5 years in Blantyre, Malawi: an observational, population-level, serosurveillance study](#)

Todd D Swarthout, et al.

Review

[Prevention of monkeypox with vaccines: a rapid review](#)

Gregory A Poland, Richard B Kennedy, Pritish K Tosh

Personal View

[The Johns Hopkins University Center for Systems Science and Engineering COVID-19 Dashboard: data collection process, challenges faced, and lessons learned](#)

Ensheng Dong, et al.

Lancet Public Health

Dec 2022 Volume 7 Number 12 e983-e1090

<https://www.thelancet.com/journals/lanpub/issue/current>

Editorial

[The fate of public health in China](#)

The Lancet Public Health

Health Policy

Developing an effective and sustainable national immunisation programme in China: issues and challenges

Shu Chen, et al.

Lancet Respiratory Medicine

Dec 2022 Volume 10 Number 12 p1099-1188, e107-e116

<https://www.thelancet.com/journals/lanres/issue/current>

[New issue; No digest content identified]

Maternal and Child Health Journal

Volume 26, issue 11, November 2022

<https://link.springer.com/journal/10995/volumes-and-issues/26-11>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 43 Issue 1, January 2023

<http://mdm.sagepub.com/content/current>

[New issue; No digest content identified]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 100, Issue 3 Pages: 617-961 September 2022

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Nature

Volume 612 Issue 7939, 8 December 2022

<https://www.nature.com/nature/volumes/612/issues/7939>

[New issue; No digest content identified]

Nature Biotechnology

Volume 40 Issue 11, November 2022

<https://www.nature.com/nbt/volumes/40/issues/11>

News 08 Nov 2022

For hemophilia and thalassemia, a new era of 'one-and-done' gene therapies has arrived

Industry celebrates two newly approved genetic medicines, but patients with these blood disorders may face a long wait, and many will never access them because of their high cost.

Cormac Sheridan

Review Article 03 Nov 2022

Unlocking the promise of mRNA therapeutics

mRNA therapeutics face more challenges than mRNA vaccines, but solutions are on the horizon.

Eduarde Rohner, Ran Yang, Kenneth R. Chien

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 10 Dec 2022)

[No new digest content identified]

Nature Genetics

Volume 54 Issue 12, December 2022

<https://www.nature.com/ng/volumes/54/issues/12>

Editorial 05 Dec 2022

Genetic futurism

Large-scale genotyping and phenotyping efforts, including biobanks, have revolutionized our understanding of the genetic architecture of human traits and diseases. Years of ever-larger genome-wide association studies (GWAS) have produced a catalog of genetic variants that contribute to complex traits. A corollary of this research has been the development of personalized polygenic scores (PGS) or polygenic risk scores (PRS).

Comment 29 Nov 2022

Mapping the Arab genome

The Qatar Genome Program was established to interrogate the genomics and genetics of populations in the Middle East. Improving precision medicine strategies and building long-term research capacity are both key aims of the initiative.

Hamdi Mbarek, Said I. Ismail

Nature Human Behaviour

Volume 6 Issue 11, November 2022

<https://www.nature.com/nathumbehav/volumes/6/issues/11>

[Reviewed earlier]

Nature Medicine

Volume 28 Issue 11, November 2022

<https://www.nature.com/nm/volumes/28/issues/11>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 21 Issue 12, December 2022

<https://www.nature.com/nrd/volumes/21/issues/12>

Comment 17 Oct 2022

The NCATS Assay Guidance Manual programme: advancing the practice and rigour of preclinical translation

The Assay Guidance Manual programme, a translational science education and training initiative at the US National Center for Advancing Translational Sciences (NCATS), aims to help bridge the gap

between research discoveries and the delivery of new therapies by creating and disseminating experimental protocols and standards for rigour in preclinical translational research.
Sarine Markossian, Kyle R. Brimacombe, Matthew D. Hall

An Audience With 11 Nov 2022

COVID vaccines: "We flew the aeroplane while we were still building it"

Recently retired head of vaccine R&D at Pfizer, Kathrin Jansen, discusses the lightning speed development of SARS-CoV-2 vaccines — and the implications for vaccine platforms.
Katie Kingwell

Nature Reviews Genetics

Volume 23 Issue 12, December 2022

<https://www.nature.com/nrg/volumes/23/issues/12>

[New issue; No digest content identified]

Nature Reviews Immunology

Volume 22 Issue 12, December 2022

<https://www.nature.com/nri/volumes/22/issues/12>

Comment 25 Oct 2022

Principles of disease defence in organisms, superorganisms and societies

Social insects such as ants form a superorganism in which individual colony members cooperate for disease defence, much like the cells of an organism. Studying social insect colonies can help to determine common principles that unite the disease defences of organisms, superorganisms and societies.

Sylvia Cremer, Michael Sixt

New England Journal of Medicine

December 8, 2022 Vol. 387 No. 23

<https://www.nejm.org/toc/nejm/medical-journal>

Editorials

Audio Interview: Covid-19 and Health Equity

E.J. Rubin, L.R. Baden, M. Hlatshwayo Davis, and S. Morrissey

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 10 Dec 2022]

[No new digest content identified]

Pediatrics

Volume 150, Issue 5 November 2022

<https://publications.aap.org/pediatrics/issue/150/5>

Articles

[Reviewed earlier]

PharmacoEconomics

Volume 40, issue 12, December 2022

<https://link.springer.com/journal/40273/volumes-and-issues/40-12>

[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 10 Dec 2022)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 10 Dec 2022)

[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 10 Dec 2022)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 10 Dec 2022)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 10 Dec 2022]

Research Article

[Frameworks for mitigating the risk of waterborne diarrheal diseases: A scoping review](#)

Chisala D. Meki, Esper J. Ncube, Kuku Voyi

Research Article | published 09 Dec 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0278184>

[Rural parents' attitudes and beliefs on the COVID-19 pediatric vaccine: An explanatory study](#)

Rachael Lacy, Jini Puma, Michael Tubolino, David LaRocca, Lori A. Crane, Lisa Miller, Chad D. Morris, Sean T. O'Leary, Jenn A. Leiferman

Research Article | published 07 Dec 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0278611>

[Self-correction in science: The effect of retraction on the frequency of citations](#)

Anton Kühberger, Daniel Streit, Thomas Scherndl
Research Article | published 07 Dec 2022 PLOS ONE
<https://doi.org/10.1371/journal.pone.0277814>

[Effectiveness of Pfizer-BioNTech COVID-19 vaccine as evidence for policy action: A rapid systematic review and meta-analysis of non-randomized studies](#)

Megan Wallace, Jennifer P. Collins, Heidi Moline, Ian D. Plumb, Monica Godfrey, Rebecca L. Morgan, Doug Campos-Outcalt, Sara E. Oliver, Kathleen Dooling, Julia W. Gargano
Research Article | published 06 Dec 2022 PLOS ONE
<https://doi.org/10.1371/journal.pone.0278624>

[Beliefs regarding COVID-19 vaccinations of young adults in the United Kingdom: An interview study applying the Integrated Change Model](#)

Ilja van Bergen, Sophie Böger, Charlotte Beaudart, Mickaël Hiligsmann, Kei Long Cheung
Research Article | published 06 Dec 2022 PLOS ONE
<https://doi.org/10.1371/journal.pone.0277109>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>
[Accessed 10 Dec 2022]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

December 13, 2022 vol. 119 no. 50
<https://www.pnas.org/toc/pnas/119/50>
[New issue; No digest content identified]

Prehospital & Disaster Medicine

Volume 37 - Supplement S2 - November 2022
<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>
Abstracts of World Health Organization Emergency Medical Teams Global Meeting 2022

Preventive Medicine

Volume 164 November 2022
<https://www.sciencedirect.com/journal/preventive-medicine/vol/164/suppl/C>
[Reviewed earlier]

Proceedings of the Royal Society B

07 December 2022 Volume 289 Issue 1988
<https://royalsocietypublishing.org/toc/rspb/current>
[New issue; No digest content identified]

Public Health

Volume 213 Pages 1-198 (December 2022)

<https://www.sciencedirect.com/journal/public-health/vol/213/suppl/C>

Review article Full text access

[Smallpox vaccination and vaccine hesitancy in the Kingdom of the Two Sicilies \(1801\) and the great modernity of Ferdinand IV of Bourbon: a glimpse of the past in the era of the SARS-COV-2 \(COVID-19\) pandemic](#)

M. Martini, M. Bifulco, D. Orsini

Pages 47-53

Review article Open access

[Features of human papillomavirus vaccination education strategies in low- and middle-income countries: a scoping review](#)

E.A. Marfo, K.D. King, C.A. Adjei, S.E. MacDonald

Pages 61-67

Public Health Ethics

Volume 15, Issue 1, April 2022

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Reports

Volume 137 Issue 6, November/December 2022

<https://journals.sagepub.com/toc/phrg/137/6>

[Reviewed earlier]

Qualitative Health Research

Volume 32 Issue 14, December 2022

<https://journals.sagepub.com/toc/qhra/current>

[New issue; No digest content identified]

Research Ethics

Volume 18 Issue 4, October 2022

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 10 Dec 2022]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Selected Articles

9 Dec 2022

[Use of multiple methods to measure adherence to antiretroviral treatment in La Romana, Dominican Republic](#)

Original research | Spanish |

Risk Analysis

Volume 42, Issue 10 Pages: 2125-2343 October 2022

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 10 Dec 2022]

[No new digest content identified]

Science

Volume 378| Issue 6624| 9 Dec 2022

<https://www.science.org/toc/science/current>

[New issue; No digest content identified]

Science and Engineering Ethics

Volume 28, issue 6, December 2022

<https://link.springer.com/journal/11948/volumes-and-issues/28-6>

[Reviewed earlier]

Science Translational Medicine

Volume 14| Issue 674| 7 Dec 2022

<https://www.science.org/toc/stm/current>

Research Articles

[A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria](#)

BY Sodiomon B. Sirima, et al.

07 Dec 2022

A three-dose regimen of a whole sporozoite vaccine in adults in Burkina Faso, West Africa, demonstrated safety and efficacy against malaria infection.

Social Science & Medicine

Volume 314 December 2022

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/314/suppl/C>

Discussion Abstract only

[Considering multiple governance levels in epidemiologic analysis of public policies](#)

Alina S. Schnake-Mahl, Jaquelyn L. Jahn, Jonathan Purtle, Usama Bilal

Article 115444

Review article Open access

[Assessing the World Health Organization: What does the academic debate reveal and is it democratic?](#)

Fabian Moser, Jesse B. Bump

Article 115456

Review article Abstract only

[Why do people believe health misinformation and who is at risk? A systematic review of individual differences in susceptibility to health misinformation](#)

Xiaoli Nan, Yuan Wang, Kathryn Thier

Article 115398

Research article Full text access

[Mistrust in public health institutions is a stronger predictor of vaccine hesitancy and uptake than Trust in Trump](#)

Yongjin Choi, Ashley M. Fox

Article 115440

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 10 Dec 2022]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 43, issue 5-6, December 2022

<https://link.springer.com/journal/11017/volumes-and-issues/43-5>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 50 November–December 2022

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/50/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 27, Issue 11 Pages: i-iv, 941-1023 November 2022

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 40, Issue 49 Pages 7011-7166 (22 November 2022)

<https://www.sciencedirect.com/journal/vaccine/vol/40/issue/49>

Selected Content

Discussion No access

Moral injury in health care: A focus on immunization

Rosemary Ricciardelli, Noni E. MacDonald

Pages 7011-7013

Research article Abstract only

Opinions, attitudes, and barriers to pediatric vaccination in Argentina

A. Urueña, J.I. Ruiz, D.A. Lew, J. David, ... C. Vizzotti

Pages 7042-7049

Research article Abstract only

Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly

Shu-ling Hoshi, Aiko Shono, Xerxes Seposo, Reiko Okubo, Masahide Kondo

Pages 7057-7064

Research article Open access

Developing communication tools on rotavirus vaccination to support family paediatricians in Italy

Federico Marchetti, Giulia Lamiani, Marco Bona, Chiara Amerighi, ... Giorgio Conforti

Pages 7108-7114

Research article Full text access

The resurgence risk of COVID-19 in China in the presence of immunity waning and ADE: A mathematical modelling study

Weike Zhou, Biao Tang, Yao Bai, Yiming Shao, ... Sanyi Tang

Pages 7141-7150

Research article Full text access

Identifying early adopters of COVID-19 vaccines in Latin America

Alejandro Arrieta, Ariadna García-Prado, Juan Pablo Sarmiento, Carmen Paz Castro

Pages 7158-7166

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 10 Dec 2022]

Latest Articles

Open Access Article

Parental Attitudes, Intentions, Decisions, and Psychological Wellbeing Regarding COVID-19 Vaccination: Preschool, School-Age, and Adolescent Caregivers

by Liang-Jen Wang

Open Access Article

Parental Seasonal Influenza Vaccine Hesitancy and Associated Factors in Shanghai, China, during the COVID-19 Pandemic: A Cross-Sectional Study

by Jingyi Fan

Open Access Article

Knowledge and Attitude Regarding Monkeypox Virus among Physicians in Saudi Arabia: A Cross-Sectional Study

by Najim Z. Alshahrani

Open Access Article

A Descriptive Analysis of the Relationship between Social Media Use and Vaccine Hesitancy among a Sample of Unvaccinated Adults in Canada

by Thomas Yen-Ting Chen

Value in Health

December 2022 Volume 25 Issue 12 p1925-2080

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

.....
.....

Contents [click to move among sections]

:: *Coronavirus [COVID-19] - WHO*

:: *Organization Announcements*

:: *Journal Watch*

:: *Pre-Print Servers*

.....
.....

Pre-Print Servers

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

Selected Research

Research Article metrics AWAITING PEER REVIEW

Circulation of respiratory viruses during the COVID-19 pandemic in The Gambia [version 1; peer review: awaiting peer review]

Sheikh Jarju, Elina Senghore, Helen Brotherton, Alasana Saidykhan, Samba Jallow, Edrissa Krubally, Edrisa Sinjanka, Morris Ngor Ndene, Fabakary Bajo, Musa M Sanyang, Binta Saidy, Alasana Bah, Nuredin I Muhammed, Karen Forrest, Ed Clarke, Umberto Dalessandro, Abdul K Sesay, Effua Usuf, Carla Cerami, Anna Roca, Beate Kampmann, Thushan I de Silva

Peer Reviewers Invited

Funders

Bill and Melinda Gates Foundation

Global Challenge Research Fund award from The University of Sheffield

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Filter: All articles]

Selected Research

[Serious harms of the COVID-19 vaccines: a systematic review](#)

Peter C Gøtzsche, Maryanne Demasi

medRxiv 2022.12.06.22283145; doi: <https://doi.org/10.1101/2022.12.06.22283145>

[Cholera past and future in Nigeria: are the Global Task Force on Cholera Control's 2030 targets achievable?](#)

Gina E C Charnley, Sebastian Yennan, Chinwe Ochu, Ilan Kelman, Katy A M Gaythorpe, Kris A Murray

medRxiv 2022.12.06.22283154; doi: <https://doi.org/10.1101/2022.12.06.22283154>

[Efficacy of a bivalent \(D614 + B.1.351\) SARS-CoV-2 Protein Vaccine](#)

Gustavo H. Dayan, Nadine Rouphael, Stephen R. Walsh, Aiyang Chen, Nicole Grunenberg, Mary Allen, Johannes Antony, Kwaku Poku Asante, Amit Suresh Bhate, Tatiana Beresnev, Matthew I Bonaparte, Maria Angeles Ceregido, Dmytro Dobrianskyi, Bo Fu, Marie-Helene Grillet, Maryam Keshtkar-Jahromi, Michal Juraska, Jia Jin Kee, Hannah Kibuuka, Marguerite Koutsoukos, Roger Masotti, Nelson L. Michael, Humberto Reynales, Merlin L. Robb, Sandra M. Villagómez Martínez, Fredrick Sawe, Lode Schuerman, Tina Tong, John Treanor, T. Anh Wartel, Carlos A. Diazgranados, Roman M. Chiciz, Sanjay Gurunathan, Stephen Savarino, Saranya Sridhar, the VAT00008 study team

medRxiv 2022.12.05.22282933; doi: <https://doi.org/10.1101/2022.12.05.22282933>

[Strategies and interventions to strengthen pharmacovigilance systems in low- and middle-income countries: a scoping review](#)

Olga Menang, Andrea de Soyres-Kuemmerle, Karen Maigetter, Christian Burri

medRxiv 2022.12.06.22283123; doi: <https://doi.org/10.1101/2022.12.06.22283123>

[COVID-19 vaccine coverage targets to inform reopening plans in a low incidence setting](#)

Eamon Conway, Camelia Walker, Chris Baker, Michael Lydeamore, Gerard E. Ryan, Trish Campbell, Joel C. Miller, Max Yeung, Greg Kabashima, James Wood, Nic Rebuli, James M. McCaw, Jodie McVernon, Nick Golding, David J. Price, Freya M. Shearer

medRxiv 2022.12.04.22282996; doi: <https://doi.org/10.1101/2022.12.04.22282996>

[Understanding the impact of disease and vaccine mechanisms on the importance of optimal vaccine allocation](#)

Isobel R. Abell, James M. McCaw, Christopher M. Baker

medRxiv 2022.06.30.22277126; doi: <https://doi.org/10.1101/2022.06.30.22277126> Revision

[Monkeypox knowledge, concern, willingness to change behaviour, and seek vaccination: Results of a national cross-sectional survey](#)

James MacGibbon, Vincent Cornelisse, Anthony K J Smith, Timothy R Broady, Mohamed A Hammoud, Benjamin R Bavinton, Heath Paynter, Matthew Vaughan, Edwina J Wright, Martin Holt

medRxiv 2022.12.01.22282999; doi: <https://doi.org/10.1101/2022.12.01.22282999>

The Societal Value of Vaccines: Expert-Based Conceptual Framework and Methods Using COVID-19 Vaccines as A Case Study

Manuela Di Fusco, Diana Mendes, Lotte Steuten, David E Bloom, Michael Drummond, Katharina Hauck, Jonathan Pearson-Stuttard, Rachel Power, David Salisbury, Adrian Towse, Julie Roiz, Gabor Szabo, Jingyan Yang, Kinga Marczell

medRxiv 2022.12.02.22283046; doi: <https://doi.org/10.1101/2022.12.02.22283046>

Evaluating primary and booster vaccination prioritization strategies for COVID-19 by age and high-contact employment status using data from contact surveys

Ethan Roubenoff, Dennis Feehan, Ayesha S. Mahmud

medRxiv 2022.12.02.22283040; doi: <https://doi.org/10.1101/2022.12.02.22283040>

Battle of Polio eradication in the Western Pacific Region in the transition to COVID-19 endemicity

Ruobing Mei, Shirley L. L. Kwok, Eric H. Y. Lau, Tiffany H. K. Lo, Joseph T. Wu, Leesa K. Lin, Kathy Leung

medRxiv 2022.11.30.22282954; doi: <https://doi.org/10.1101/2022.11.30.22282954>

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Accessed 10 Dec 2022]

[Provider Filter: OSF Pre-prints Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]

Trusted Research: a Primer from CPNI

UK Reproducibility Network

Last edited: Dec 10, 2022 UTC

Social and Behavioral Sciences Life Sciences Engineering Business Arts and Humanities Education Medicine and Health Sciences Law Physical Sciences and Mathematics Architecture

Trusted Research is official Government guidance for the UK research sector. It was developed in consultation with academia and jointly published by the Centre for Protection of National Infrastructure (CPNI) and the National Cyber Security Centre (NCSC).

OSF Preprints

Questions of ethics during the Covid-19 pandemic emerging from problems of data fraud and health risks

Tam-Tri Le

Ruining Jin

Minh-Hoang Nguyen

Last edited: Dec 9, 2022 UTC

Life Sciences Medicine and Health Sciences Social and Behavioral Sciences

In more than two years of the global health crisis of the Covid-19 pandemic, ethical issues regarding health data have been emerging quickly to the central focus of the global scientific community. Many papers have been retracted because of data problems, including those from prestigious journals. F ...

OSF Preprints

Open Research: Examples of good practice, and resources across disciplines

Emily K. Farran
Priya Silverstein
Aminath A. Ameen
Iliana Misheva
Camilla Gilmore

Last edited: Dec 8, 2022 UTC

Architecture Medicine and Health Sciences Physical Sciences and Mathematics Business Law Arts and Humanities Engineering Education Life Sciences Social and Behavioral Sciences

Open research is best described as “an umbrella term used to refer to the concepts of openness, transparency, rigor, reproducibility, replicability, and accumulation of knowledge” (Crüwell et al., 2019, p. 3). Although a lot of open research practices have commonly been discussed under the term “ope ... OSF Preprints

Wellcome Open Research [to 10 Dec 2022]

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 10 Dec 2022]

Selected Research

Research Article Open Access

[Achieving good health with a low environmental footprint – A comparison of national indicators \[version 1; peer review: awaiting peer review\]](#)

Connor Mustard, et al.

Background

Integrated metrics that account for resource use and human health are essential to help identify and support human development pathways that safeguard planetary health. We identify countries that achieved the highest levels of health and development at the lowest cost to Earth’s natural capital and report ecological within-country analyses of associations between indicators of environmental sustainability, human health, and development...

Systematic Review Open Access

[Probiotics for preventing or treating COVID-19; a systematic review of research evidence and meta-analyses of efficacy for preventing death, severe disease, or disease progression \[version 1; peer review: awaiting peer review\]](#)

Jawara Allen, Carlton A. Evans, Sumona Datta

* * * *

Think Tanks

Brookings [to10 Dec 2022]

<http://www.brookings.edu/>

Latest Research [Selected]

Essay

[17 Rooms: Rejuvenating the Sustainable Development Goals through shared action](#)

John W. McArthur, Zia Khan, Jacob Taylor, Alexandra Bracken, and Daniel Bicknell

Wednesday, December 7, 2022

Executive summary

The 17 Rooms initiative continues to drive action across all the Sustainable Development Goals (SDGs), using unique approaches to help groups unlock and accelerate diverse paths to progress. In the 17 Rooms 2022 flagship, 17 highly curated working groups, one per SDG, came together to craft “next step” actions on priorities ranging from prototyping digital data cooperatives in South Asia, to updating African food and protein policies, and reimagining the role of education systems in climate action worldwide. Several Rooms brought unconventional allies together to prompt new waves of momentum and new forms of accountability. Several focused on actions to bridge environmental and societal outcomes, while others pursued localized tools to tackle global challenges. Meanwhile, in the spirit of enabling local leadership on the SDGs, 17 Rooms-X (or simply “17-X”) offers a widely accessible approach to help communities of all scales take SDG action into their own hands. In 2023, people around the world are invited to bring their own ideas and direct engagement to the 17 Rooms movement.

Center for Global Development [to 10 Dec 2022]

<https://www.cgdev.org/>

All Research [Selected]

BRIEFS

Estimating Japan's Return on Investment from an Ambitious Program to Incentivize New Antibiotics

Rachel Silverman And Adrian Towse

December 08, 2022

Drug-resistant infections kill an estimated 23,210 Japanese citizens every year. The government of Japan is considering a program that would provide minimum guaranteed revenue to the successful developers of new antibiotics. We present the results of a modelling exercise to estimate the likely retur...

BRIEFS

Estimating the UK's Return on Investment from an Ambitious Program to Incentivize New Antibiotics

Rachel Silverman and Adrian Towse

December 08, 2022

Drug-resistant infections kill an estimated 7,600 UK citizens every year. Without investment for new antimicrobials, deaths from drug-resistant infections could increase dramatically in the coming decade. We present the results of a modelling exercise to estimate the likely ROI from an expanded prog...

BRIEFS

Estimating the EU's Return on Investment from an Ambitious Program to Incentivize New Antibiotics

Rachel Silverman and Adrian Towse

December 08, 2022

Drug-resistant infections kill an estimated 33,000 EU citizens every year. Without sufficient investment for new antimicrobials, deaths from drug-resistant infections could increase dramatically in the coming decade. We present the results of a modelling exercise to estimate the likely ROI from ince...

BRIEFS

Estimating Canada's Return on Investment from an Ambitious Program to Incentivize New Antibiotics

Rachel Silverman and Adrian Towse

December 08, 2022

Drug-resistant infections kill an estimated 5,400 Canadian citizens every year. Without sufficient R&D investment for new antimicrobials, deaths from drug-resistant infections could increase dramatically in the coming decade. We present the results of a modelling exercise to estimate the likely ROI ...

Chatham House [to 10 Dec 2022]

<https://www.chathamhouse.org/>

Selected Analysis, Comment

No new digest content identified.

CSIS [to 10 Dec 2022]

<https://www.csis.org/>

Selected Reports, Events

No new digest content identified.

Kaiser Family Foundation [to 10 Dec 2022]

https://www.kff.org/search/?post_type=press-release

Newsroom

COVID-19 Vaccines Could Cost Billions of Dollars More Each Year If the Federal Government Ends Its Bulk Purchasing Program

December 7, 2022 *News Release*

If the federal government runs out of money to purchase COVID-19 vaccines, the per-dose price likely would skyrocket and could increase spending on vaccines by billions of dollars a year, a new KFF analysis finds. To date, the federal government has spent more than \$30 billion on COVID-19 vaccines to...

The Nation's Largest For-Profit Health Systems Have Typically Had Operating Margins That Meet or Exceed Pre-Pandemic Levels

December 5, 2022 *News Release*

Despite higher inflation and dwindling COVID-19 relief funding from the federal government, the nation's largest for-profit health systems so far this year have operating margins that meet or exceed levels in 2019 prior to the pandemic, a new KFF analysis finds. The analysis examines the financial performance of the three...

McKinsey Global Institute

<https://www.mckinsey.com/mgi/overview>

Latest Research

Pixels of Progress: A granular look at human development around the world

Our world is big and complex, but human progress is still about life on the ground, up close and in detail.

December 7, 2022 – In this new report, we share the findings from a new dataset that breaks the world down into more than 40,000 microregions, a view 230 times more granular than a country perspective. This pixelated version of the world, compiled with cutting-edge statistical techniques like the use of night-time satellite imagery, provides a much more nuanced view of development than previous research, enhancing our understanding of global progress in ways that can help business and governments make better, more targeted decisions....

ODI [Overseas Development Institute] [to 10 Dec 2022]

<https://odi.org/en/publications/>

Publications [Selected]

No new digest content identified.

Pew Research Center [to 10 Dec 2022]

<https://www.pewresearch.org/>

Latest Publications [Selected]

report | Dec 6, 2022

[Social Media Seen as Mostly Good for Democracy Across Many Nations, But U.S. is a Major Outlier](#)

Most think social media has made it easier to manipulate and divide people, but they also say it informs and raises awareness.

short read | Dec 6, 2022

[In advanced and emerging economies, similar views on how social media affects democracy and society](#)

People in advanced and emerging economies have mixed feelings about social media's impact on political life.

Rand [to 10 Dec 2022]

<https://www.rand.org/pubs.html>

Published Research [Selected]

Journal Article

[Misinformation, Anticipated Regret, and Vaccine-Related Behaviors](#)

A national survey (N = 1025) conducted in August 2021 reveals that Americans' belief in misinformation about COVID-19 was negatively associated with vaccine acceptance.

Dec 6, 2022

Jody Chin Sing Wong, Janet Z. Yang

Urban Institute [to 10 Dec 2022]

<https://www.urban.org/publications>

[New Research Publications](#)

Research Report

[The Impact of the COVID-19 Public Health Emergency Expiration on All Types of Health Coverage](#)

December 5, 2022

... We estimate that if the PHE expires in April 2023, 18.0 million people will lose Medicaid coverage in the following 14 months. Of those, about 3.2 million children are estimated to transition from Medicaid to separate Children's Health Insurance Programs, about 3.8 million people will become uninsured, about 9.5 million people will either newly enroll in employer-sponsored insurance after losing Medicaid or transition to employer-sponsored insurance as their only source of coverage after being enrolled in both employer-sponsored insurance and Medicaid sometime during the PHE, and more than 1 million people will enroll in the nongroup market, most of whom will be eligible for premium tax credits in the Marketplace.

World Economic Forum [to 10 Dec 2022]

<https://agenda.weforum.org/news/>

Media

No new digest content identified.

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2022. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the [Bill & Melinda Gates Medical Research Institute](#) , [PATH](#), and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*